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Abstract
MICHAEL A. HUSSEY: Extensions of Nonparametric
Randomization-Based Analysis of Covariance
(Under the direction of Gary G. Koch)
Nonparametric Randomization-Based Analysis of Covariance (Koch et. al. (1998))
provides covariate-adjusted estimates of treatment effects for randomized clinical tri-
als. It has application in the regulatory setting where analyses are specified a priori,
and any statistical assumptions of parametric methods are not verifiable until after
data collection. Using (1) a vector containing differences in means of outcomes and
differences in means of baseline covariables between the two randomized groups and
(2) an empirical covariance matrix for the vector, weighted least squares is applied to
force the difference in means of baseline covariables to zero (as expected with valid ran-
domization) to obtain covariate-adjusted estimates. The covariate-adjusted estimates
have a population-averaged interpretation and only require a valid randomization and
adequate sample size (for approximate normal distributions). Saville and Koch (2012)
have developed methodology combining cross-products of DFBETA residuals from a
treatment-only model with covariate information to obtain a covariance matrix for use
in the nonparametric covariate adjustment.
For this research, the methodology is extended to analysis of matched sets with a di-
chotomous outcome. In the 1:1 setting with randomization or M:1 setting, methods are
provided for obtaining an adjusted difference in proportions and an adjusted odds ratio,
including techniques for obtaining an exact p-value (for the difference). Application of
the methods to the 1:1 observational matched case-control study is also described.
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For larger strata, the methods of Saville and Koch are expanded to obtain stratified
covariate-adjusted log odds ratios (in the case of dichotomous outcomes) or stratified
covariate-adjusted log hazard ratios (in the case of time-to-event outcomes).
The methods of Saville and Koch are further developed for randomization to mul-
tiple treatment groups. Methodology is provided for creation of the appropriate co-
variance matrix to use in the nonparametric covariance adjustment, and a strategy for
accommodating a time-varying treatment effect is presented.
These methods avoid modeling assumptions for the covariates (e.g. proportional
hazards, functional form) while providing increased precision for the estimated treat-
ment effects. Their use is intended for primary analysis of a randomized clinical trial,
with supportive secondary parametric analyses having application to subgroup analyses
or assessment of interactions with treatment.
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Chapter 1
Introduction and Literature Review
Analysis of Covariance (ANCOVA) has long been used as a way of assessing the
relationship between a variable and an outcome measure in the presence of other vari-
ables. In an observational study, ANCOVA may be used when there is interest in
assessing the risk of disease associated with an exposure while adjusting for potential
confounders. Covariance adjustment is desired in this setting so as to reduce bias in
measuring the association between the exposure and risk of disease. In the randomized
clinical trial setting, ANCOVA may be used to assess the effect of a treatment on an
outcome measured after the treatment period while adjusting for a subject’s baseline
measurement. Covariance adjustment is desired in this setting so as to increase the
precision of the estimated treatment effect and increase statistical power of hypothesis
tests.
In general, covariance adjustment is desirable when analysis goals may involve (1)
the reduction of bias due to potential confounding in an observational study, (2) the
reduction of variance of an estimated treatment effect in a randomized clinical trial by
adjusting for highly predictive covariables, (3) correcting minor imbalances in the dis-
tributions of baseline variables between the treatment groups which may have occurred
during randomization, (4) clarification of whether statistical significance of unadjusted
treatment effects would otherwise be explained by other factors, and (5) through inter-
action, assessment of possible heterogeneity of treatment effects across groups defined
by other factors (Snedocor and Cochran, 1980).
For continuous outcomes, parametric ANCOVA methods such as linear regression
rely on the assumptions of independence of observations, homogeneity of error vari-
ances, correct functional form for covariates, and normality of the errors. For dichoto-
mous outcomes, logistic regression requires assumptions of independent binomial distri-
butions for the different subpopulations defined by cross-classification of the covariates
as well as correct functional forms for the covariates. For ordinal and time-to-event
outcomes, the proportional odds model and the Cox proportional hazards model re-
quire their respective assumptions of proportional odds and proportional hazards. In
the setting of a randomized clinical trial for an experimental treatment in support of
approval by a regulatory agency, all analyses on the primary endpoint must be specified
prior to data collection. The statistical assumptions related to parametric ANCOVA
methods are usually unverifiable a priori. This dilemma has led to interest in apply-
ing nonparametric randomization-based ANCOVA methods to data from randomized
clinical trials.
1.1 Development of General Nonparametric Randomization-
Based ANCOVA
Details for general methodology of nonparametric randomization-based ANCOVA
can be found in Koch, Amara, et. al. (Koch et al., 1982) as well as the appendix
of Koch, Tangen, et. al. (Koch et al., 1998). Let yik denote a univariate response
for patient k randomized to treatment i in a clinical trial. Here, k = 1, . . . , ni and
i = 1, 2. Additionally, let xik = (xik1, . . . , xikP )
′ denote the vector of P covariables for
the kth patient on treatment i. Then the sample mean of the responses and the sample
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mean of the covariates for patients on treatment i are given as y¯i =
1
ni
∑ni
k=1 yik and
x¯i =
1
ni
∑ni
k=1 xik. Further, let f = (dy,d
′
x)
′ where dy = (y¯1 − y¯2) and dx = (x¯1 − x¯2).
Thus f is a vector containing the difference in mean responses and the difference in
means of covariables between the two treatment groups. In the case of a continuous
outcome, f exists as stated. In the case of other types outcomes, the dy may undergo
transformation or represent a difference in mean scores rather than a strict difference
in sample means.
A covariance matrix for f can be generated in one of two ways. Under a null
hypothesis of no treatment effect, a randomization distribution can be derived under
an expectation that a patient’s response would be the same on either treatment. The
covariance matrix that is created, V 0, has the form in (1.1).
V0 =
n
n1n2(n− 1)
n∑
k=1
 (y∗k − y¯∗∗)2 (y∗k − y¯∗∗)(xk − x¯∗)′
(y∗k − y¯∗∗)(xk − x¯∗)′ (xk − x¯∗)(xk − x¯∗)′
 (1.1)
Here, n = n1+n2, y∗k is the response under the null hypothesis for patient k (irrespective
of treatment assignment), y¯∗∗ is the sample mean of all patients in the trial under the
null hypothesis, and x¯∗ is the sample mean vector of covariates for all patients in the
trial. Since this covariance matrix is developed using a randomization distribution
based on a finite sample (i.e. those enrolled in the clinical trial), inference is confined
to the population of patients enrolled on the trial.
Alternatively, a covariance matrix can be created under the assumption that the
trial patients are a simple random sample from a larger population. Then the covariance
Vs can be defined as in (1.2):
Vs =
2∑
i=1
1
ni(ni − 1)
ni∑
k=1
 (yik − y¯i)2 (yik − y¯i)(xk − x¯i)′
(yik − y¯i)(xk − x¯i)′ (xk − x¯i)(xk − x¯i)′
 (1.2)
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This covariance matrix allows inference to the larger population from which the trial pa-
tients were sampled, thus allowing for population-based (i.e. unconditional) inferences
after covariate adjustment.
The linear model f = Zb can be fit using weighted least squares methodology, where
Z = (1 0′P )
′ with 0P representing a zero vector of length P . This model specification
forces the difference in means of the covariables to zero, which is what is expected under
the assumption of a valid randomization. An estimator for b can then be obtained as
b = (Z ′V −1Z)−1Z ′V −1f where V is either V0 or Vs. An estimator for the variance of
b, V b, can be obtained as V b = (Z
′V −1Z)−1. This estimator corresponds to the exact
variance of the randomization distribution of b if V = V0. Otherwise, the estimator
corresponds to a consistent estimator of the variance of b if Vs is used.
Test statistics can be formed for the comparison of the two treatments using b
and its variance estimate V b. When sample sizes are large enough for b to have an
approximate normal distribution (i.e. each treatment group has at least 15
√
P + 1
patients), Qb = b
2/V b will have an approximate chi-square distribution with 1 degree
of freedom (Koch et al., 1998). If Vs is used in the weighted least squares analysis,
large-sample confidence intervals for the treatment difference can be obtained through
the use of b and V b. For small samples, an exact p-value for the test of the treatment
effect can be obtained (through a permutation test) when V0 is used as the covariance
matrix of f . Since the weighted least squares analysis using Z forces the difference in
the means of the covariables between the two groups to zero, it may be of interest to
assess the extent of random imbalances in the covariables from randomization. Using
the V0 covariance matrix, one can create the test statistic Q0 = d
′
xV
−1
xxdx which will
have P degrees of freedom. Here, V xx is the partition of V representing the covariance
matrix of the vector of mean differences in the covariables. A non-significant p-value
for the test of Q0 would suggest goodness-of-fit in the sense that there is no evidence
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of a violation of the assumption of a valid randomization.
The methodology described above is a general framework for producing nonpara-
metric covariate-adjusted estimates of a treatment effect in a randomized clinical trial.
The main assumption is that there is a valid randomization to the treatment groups
so that the distributions of covariables are reasonably similar across the two treatment
groups. In the analysis described above, weighted least squares forces the difference
in means of the covariables between the two treatment groups to zero in line with ex-
pected differences under a valid randomization. With large enough sample sizes, the
covariate-adjusted estimates will have approximate normal distributions. The choice of
the covariance matrix used in the analysis will affect whether inference is restricted to
the study population or whether inference pertains to a large population from which
the study participants were randomly sampled.
There are some limitations to the methodology described above. Unlike standard
parametric regression approaches, estimates for the association between the covariables
and the response are not obtained. Usually this is not of concern, as the treatment
effect is generally the main association of interest in a randomized trial. Additionally,
as with any analysis of covariance, covariables should be chosen a priori so as to avoid
selection bias from choosing adjustment variables based on their relationship to the
outcome. Finally, the methodology presented here does not accommodate interactions
of covariates with treatment. However, estimation of treatment effects by levels of an
additional variable may be suitable in a supportive parametric analysis after statistical
significance of the treatment effect is established through the nonparametric analysis.
The estimated treatment effect obtained from the nonparametric ANCOVA here
should also be emphasized as representing a population-averaged treatment effect. In
parametric regression approaches, the estimated treatment effect is conditional in that it
only applies within subpopulations which share the same values of the covariables. Only
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in the unadjusted (treatment-only) parametric model would the estimated treatment
effect be population-averaged. Thus, the nonparametric ANCOVA methods tend to
be better suited to situations where interest is in an overall treatment effect rather
than one applying to certain subgroups of patients. It has been the recommendation of
authors (Koch et al., 1998),(LaVange, Durham and Koch, 2005) that the nonparametric
ANCOVA methods be reserved for analyzing the primary endpoint of a clinical trial
and that parametric regression models be supportive in secondary exploratory analyses
seeking to assess which subgroups may show greater benefit.
Given the flexibility of the above methodology to a variety of statistical outcomes,
much research has been conducted in recent years involving the application of the
nonparametric ANCOVA methods to different settings. The following sections detail
extensions of the methods to dichotomous, ordinal, and survival outcomes, as well as
discussing stratification and a hybrid methodology which uses parametric regression
diagnostics to obtain a covariance matrix for use in a nonparametric covariance adjust-
ment.
1.2 Applications to Dichotomous, Ordinal, and Survival out-
comes
The extension of nonparametric randomization-based ANCOVA to dichotomous
and ordinal outcomes is presented in Koch, Tangen, et. al. (Koch et al., 1998) and
Tangen and Koch (Tangen and Koch, 1999a). One of the main benefits of covariance
analysis is to achieve variance reduction in the estimated treatment effect. However,
due to the nonlinearity of the logit functions in logistic or proportional odds regression,
the estimated standard error of the treatment effect may increase after covariance
adjustment. This may cause some concern as to whether the parametric modeling
assumptions are satisfied. To avoid this concern, one can apply the nonparametric
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randomization-based ANCOVA methodology to a simple transformation of the outcome
measures.
Let yik be a dichotomous outcome where yik = 1 if patient k (k = 1, . . . , ni) shows a
particular response of interest on treatment i (i = 1, 2) and yik = 0 if the patient does
not show that response. Then the sample mean of the responses for each treatment
is the proportion pi = y¯i. The vector of covariables for adjustment follows the same
structure as in the general case. One can form a vector f i for each treatment group as
f i = (logit(pi), x¯
′
i)
′, where logit(p) = loge(p/(1− p)). A difference vector d = f 1 − f 2
can be created which includes the difference in the log odds of response between the
two treatments as well as differences in the means of the covariables between the two
treatment groups. The weighted least squares methodology can then be applied to
d with the model Z = (1 0′P )
′. The covariance matrix for d used in weighted least
squares is usually Vs = V 1 + V 2 since the vector d is a vector of differences between
the randomized groups. However, because a logit transformation was applied to the
response portion of d, the covariance matrix would have the form D1V 1D1 +D2V 2D2
where D1 and D2 are diagonal matrices of dimension P + 1 where the (1,1) element
of the matrices are ∂
∂p1
loge(p1/(1 − p1)) = 1p1(1−p1) and ∂∂p2 loge(p2/(1 − p2)) = 1p2(1−p2) ,
respectively, and 1’s along the rest of the diagonal. V 1 and V 2 have the same form
as in (1.2) but for each treatment group separately. Chi-square tests for the treatment
effect as well as random imbalances in the covariates can be conducted as described in
the general methodology using the appropriate covariance structures.
In the case of the proportional odds model, one can expand the vector d to accommo-
date the cumulative logits. For example, if the response variable had 4 categories (e.g.
1, 2, 3, 4), then the first three entries of d would now be log odds ratios corresponding to
the three cumulative logits. As usual, d would also contain the differences in the means
of the covariables. Analysis could proceed as described previously with a multivariate
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extension of the covariance matrix which would consider (yik − y¯i)(yik − y¯i)′ instead
of (yik − y¯i)2 and have the appropriate transformation via the relevant diagonal matri-
ces. Assessment of the treatment effect as well as random imbalances in the covariates
could proceed as previously described using Z = [Iu 0u,P ]
′ and Z = Iu+P , respec-
tively. Here, u is the number of cumulative logits, I corresponds to the identity matrix,
and 0u,P is a u×P matrix of zeroes. A test of the proportional odds assumption could
proceed with the statistic Qw = b
′C ′(CV bC ′)−1Cb where C = [−1(u−1) I(u−1)] and
1(u−1) is a vector of ones of length u− 1. Qw is approximately chi-square with degrees
of freedom corresponding to rank(C).
Tangen and Koch also discuss the use of nonparametric ANCOVA methodology
for time-to-event data (Tangen and Koch, 1999b), (Tangen and Koch, 2001). One can
form the vectors f 1 and f 2 where the first entry corresponds to the average logrank
(or Wilcoxon) score for treatments 1 and 2, respectively. Bivariate testing of both
types of scores could proceed with the first two entries of each vector corresponding
to the averages of each type of score. The covariance matrix used for the weighted
least squares portion would be based on randomization as in (1.1). Grouped survival
data can be accommodated as well where time intervals are exhaustive and mutually
exclusive. The response portion of the mean difference vector d consists of differences
in cumulative survival rates in each of the relevant time intervals t = 1, . . . , T , where
the cumulative survival rates are based on products (up through the tth interval) of
conditional probabilities of surviving through interval t given survival through the (t−
1) interval. The covariance of d is obtained through propagation of variances. A
covariance matrix based on (1.2) is obtained from examining individual event and
at-risk information for the time intervals jointly. A series of matrix operations then
transforms this matrix to obtain the covariance matrix for d. It is this matrix which
can then be used in the weighted least squares covariance adjustment. P-values for the
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treatment effects, a test for random imbalances, and assessment of homogeneity of the
treatment effects across time intervals can all be obtained by appropriately specifying
Z matrices in a manner similar to the proportional odds analysis above; however, this
approach does not provide a covariate-adjusted estimate of the hazard ratio.
1.3 Stratification
The nonparametric ANCOVA methods described thus far account for factors as
covariables. Extensions of the methodology to stratified studies have been presented
(Koch et al., 1998),(Tangen and Koch, 1999a),(Tangen and Koch, 1999b),(LaVange,
Durham and Koch, 2005). For randomized trials, a common stratification factor is
center in the context of a multi-center clinical trial. Other common stratification factors
could be geographic region or prognostic factors. For the purposes of nonparametric
randomization-based ANCOVA, two different approaches are recommended depending
on whether the strata are small (i.e. treatment group sizes within each stratum are
generally ≤ 15) or large. In the case of small strata, the difference vector dh is created
for each of the q strata (h = 1, . . . , q). Covariance matrices Vs,h are also obtained
for each stratum. A weighted difference vector dw =
∑q
h=1whdh is obtained as well
as a weighted covariance matrix Vs,w =
∑q
h=1whVs,h. Here, the wh are usually the
Mantel-Haenszel weights (Mantel and Haenszel, 1959). Weighted least squares is then
applied using dw and Vs,w. When strata are large enough, weighted least squares can
be applied within each stratum and then the estimates bh and Vb,h can be combined
over strata using the Mantel-Haenszel weights. Associated tests for the treatment effect
can be obtained as well (Koch et al., 1998).
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1.4 Other Applications
Several other applications of nonparametric randomization-based ANCOVA have
been developed in recent years. Koch and Tangen extend the methodology to non-
inferiority clinical trials (Koch and Tangen, 1999). Consider a randomized trial with
test treatment (T), reference treatment (R), and placebo (P). Interest is in making
sure that both T and R are better than placebo and that T is also non-inferior to R.
The difference vector d can take the form of (dTP ,u
′
TP , dRP ,u
′
RP )
′ where dTP and dRP
are the difference in mean responses between test and placebo as well as reference and
placebo, respectively. The uTP and uRP represent the differences in the means of the
covariables for test vs. placebo as well as reference vs. placebo. The differences in
the means of the covariables can be forced to zero through a weighted least squares
analysis which produces covariate-adjusted estimates of the differences between each
response and placebo jointly. Through an appropriate specification of Z, the ratio of
(T-P) relative to (R-P) can be assessed, and Fieller’s formula (Fieller, 1954) can be
used to obtain a confidence interval for this ratio.
Kawaguchi, Koch, and Wang extend the methodology to the case where stratified
multivariate Mann-Whitney estimators are used to compare two treatments with re-
spect to any number of finite ordinal responses (Kawaguchi, Koch and Wang, 2011).
Here, the elements of vector f include the stratification-adjusted Mann-Whitney esti-
mators for each of the responses as well as ratios comparing the two treatment groups
with respect to stratification-adjusted estimators of covariable means. A consistent co-
variance matrix for f can be obtained through propagation of variance and then used
in the usual weighted least squares analysis to obtain covariate-adjusted estimates of
the treatment effect.
Saville, LaVange, and Koch extend the methodology to the estimation of incidence
density ratios in multiple time intervals (Saville, Lavange and Koch, 2011). They
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use example data from a clinical trial for COPD where pulmonary exacerbations were
recorded as the events of interest. Considering six 6-month time intervals (3 years
of potential follow-up), the elements of the vector fhik are the counts of exacerba-
tions, the time at risk, and the covariable values for individual k on treatment i in the
hth stratum during the J time intervals. A subsequent covariance matrix Vhi can be
formed for f¯hi =
∑ni
k=1(fhik/ni). Weighted estimates of the f¯hi and the Vhi can be
formed. From these, a compound difference vector d can be formed which contains
the stratification-adjusted, log incidence density ratios comparing the two treatments
in each of the J time intervals as well as the stratification-adjusted differences in the
means of the P covariables. Weighted least squares can then be applied to d to obtain
covariate-adjusted estimates of the log incidence density ratios. Subsequent hypothesis
tests and confidence intervals can be formed, including the test to check for random
imbalances in the covariates between the treatment groups. While the procedure just
described applies an order of stratification, estimation of log incidence density ratios,
and covariate adjustment, the ordering of these three steps can be changed depending
on the number of time intervals or the size of the strata. If the number of time intervals
is small, the covariate adjustment can occur prior to estimation of the log incidence
density ratios. In the event of large strata, estimation of log incidence density ratios and
covariate adjustment can occur within strata before the covariate-adjusted estimates
are combined across the strata using some form of weighting.
A similar approach was used to estimate covariate-adjusted log hazard ratios for
multiple time intervals as in Moodie, Saville, Koch, and Tangen (Moodie et al., 2011).
Elements of the vector f ik for the kth patient on the ith treatment consist of J terms
which assess survival of the time intervals and J terms which assess whether the pa-
tient was at risk in the J pre-specified time intervals under study. This vector also
includes the covariate values for the kth patient on the ith treatment. The mean for
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each treatment f i can be formed, and an associated covariance matrix can be con-
structed. Through the propagation of variance, a vector d is formed which represents
the difference between the treatment groups with respect to log hazard ratios and the
means of the covariables. Weighted least squares then uses d and its covariance matrix
Vd to obtain covariate-adjusted estimates of the log hazard ratios for the J time inter-
vals. As in the general case, hypothesis tests for homogeneity of the log hazard ratios
from the J time intervals can be conducted along with a test of random imbalance in
the covariates between the two treatment groups.
1.5 Hybrid Methdology Using Diagnostics from Parametric
Regression Models
A common semiparametric approach to estimating a hazard ratio in the presence of
covariables is the Cox proportional hazards model for time-to-event data (Cox, 1972).
Saville and Koch proposed a covariate-adjusted log hazard ratio obtained via nonpara-
metric randomization-based ANCOVA which is closer to that of the Cox model than
what was described in Moodie et. al. (Moodie et al., 2011) (Saville and Koch, 2013).
Marginal Cox proportional hazards models containing a treatment indicator are fit for
each of K events. The K DFBETAs from these models are obtained for individuals
in each of the two treatment groups. The DFBETA for patient j (j = 1, . . . , ni) and
event k (k = 1, . . . , K) represents the approximate change to the kth estimated log
hazard ratio when the jth patient is omitted. Wei et. al. showed that an approximate
covariance matrix for the estimated log hazard ratios βˆ, Vβˆ, can be obtained by taking
the sum of the cross-products of the DFBETAs (Wei, Lin and Weissfeld, 1989). If
the elements of the difference vector d are the estimated log hazard ratios βˆ and the
differences in means of the covariables (x¯1 − x¯2), the associated covariance matrix Vd
can be assembled using V βˆ, V x¯1 + V x¯2 , and V βˆ,x¯1 − V βˆ,x¯2 . The matrix V x¯1 + V x¯2
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is the estimated covariance matrix for (x¯1 − x¯2) and V βˆ,x¯1 − V βˆ,x¯2 is the estimated
covariance of βˆ with (x¯1 − x¯2). Here, V βˆ,x¯i is the estimated covariance matrix for βˆ
and x¯i for the ith treatment group. Weighted least squares can then be applied using d
and Vd via the model Z = [IK 0KP ]
′ to obtain covariate-adjusted log hazard ratios.
Tests of homogeneity across the K log hazard ratios and random imbalance of covari-
ables between the two treatment groups can be conducted per other specifications of
Z. While this hybrid procedure is not thought to be fully nonparametric since it makes
use of a treatment-only Cox model, the p-value from the Cox model is comparable to
the nonparametric logrank test (Saville and Koch, 2013). The assumption of propor-
tional hazards for the covariates is avoided since covariate adjustment is made via the
nonparametric methodology.
1.6 A Note on Missing Data
The general nonparametric randomization-based ANCOVA methodology relies on
the assumption that the distributions of the covariables between the two treatment
groups are comparable as a consequence of a valid randomization. Exclusions of patients
for protocol violations or missingness on a covariate could potentially induce imbalance
in the covariate distribution between the two groups (Koch et al., 1998). However, the
methods would be applicable for any sort of valid multiple imputation strategy. For the
methodology in Kawaguchi, Koch, and Wang, missing data could be accommodated
when using the Mann-Whitney estimators, although a mechanism of missing completely
at random (MCAR) is assumed (Kawaguchi, Koch and Wang, 2011).
1.7 Summary of Research
The following chapters outline applications of nonparametric ANCOVA methodol-
ogy to novel settings. Chapter 2 is a direct application of the methodology to matched
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sets data with dichotomous outcomes. Nonparametric methodology is introduced for
obtaining covariate-adjusted estimates of a treatment effect for 1:1 and M :1 random-
ized studies as well as for 1:1 non-randomized matched case-control studies. Such
applications are intended for matched pairs data (as an alternative to the unadjusted
McNemar’s analysis or conditional logistic regression) or when the size of the matched
set is ≤6. Chapter 3 outlines a hybrid methodology (like that in Section 1.5) for con-
ditional likelihoods (as in conditional logistic regression) or partial likelihoods (as in
proportional hazards regression) in the presence of stratification. A treatment-only
regression model is fit, and the sum of the squared DFBETA residuals estimates the
covariance of the treatment effect which can then be used in a weighted least squares
analysis to provide covariate adjustment. Chapter 4 extends the hybrid methodology
to more than two treatment groups for time-to-event data as explored in Saville and
Koch (2012) with additional methodology for a time-varying treatment effect.
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Chapter 2
Analysis of Matched Studies with
Dichotomous Outcomes using
Nonparametric
Randomization-Based Analysis of
Covariance
2.1 Introduction
Matching may arise in clinical trials where the objective is to establish superiority
of a new treatment to a control (which may or may not be placebo). These studies may
range from a multi-center clinical trial (where subjects in the same randomization block
or from the same site form a matched set) to studies in dermatology, opthalmology,
or dentistry (where an individual’s arms/legs, eyes, or sections of the mouth form a
matched set). Matching allows for eliminating variability in the outcome among the
matched sets, thus making it a useful technique when designing a clinical study. In
the case of matched pairs for a dichotomous outcome, McNemar’s test and its related
odds ratio can be used to assess whether the subjects are more likely to experience
success (vs. failure) on a new treatment than they are on the control (McNemar,
1947). If covariate adjustment is desired for baseline variables that vary within pairs,
analysis of a binary outcome where data are from matched sets may proceed using
conditional logistic regression (Breslow and Day, 1980). In either type of analysis, log
odds ratios and their confidence intervals can be obtained to assess the effect of the
new treatment. Matched studies may also be of the form M :1, where M individuals
are randomized to treatment and one individual is randomized to control within a
matched set. In studies with blocked randomization, blocks formed as successive pairs,
triples, or groups of M + 1 patients may be matched on time of enrollment if it was
thought to be a prognostic factor. Retrospective case-control studies may also exhibit
M :1 matching, where M controls are matched to one case on variables which may be
thought to confound the relationship between an exposure variable and the odds of
being a case. For most practical purposes, M ranges between two and four subjects
(Stokes, Davis and Koch, 2012).
The NPANCOVA methodology is useful for providing covariate-adjusted estimates
of treatment effects for data from matched studies when assumptions of other methods
are not verifiable. In studies with randomization, a valid randomization is assumed so
that the differences in covariate means between the randomized groups are expected to
be zero. In the case of the observational matched case-control study (without random-
ization), the NPANCOVA methodology may be applicable provided that the exposed
and not exposed subjects within the informative matched sets have similar distributions
of other covariables across the matched sets if the matching is successful. This chap-
ter presents extensions of the NPANCOVA methodology to randomized studies with
1:1 or M :1 matching as well as an observational case-control study with 1:1 matching.
Examples presented include a randomized clinical trial with 1:1 matching, a random-
ized clinical trial with 2:1 matching, and a retrospective case-control study with 1:1
matching. Discussion of the advantages and limitations of the methodology follows the
examples.
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2.2 Methods
2.2.1 All 1:1 Matched Sets with Randomization For Paired
Difference
Let yhi = 1 denote a success on the ith treatment (i = 1, 2) for pair h (h = 1, . . . , q),
and let yhi = 0 denote a failure. Additionally, let xhi be the P×1 vector of P covariates
corresponding to the ith treatment for pair h. Within each of the respective pairs, the
two treatments have independent random allocation with equal probabilities of 0.5. A
vector of the differences in binary outcomes for the two treatments can be formed as
dh = (yh1 − yh2). The possible values for dh are as follows:
dh = yh1 − yh2 =

1 if yh1 = 1, yh2 = 0
0 if yh1 = yh2
−1 if yh1 = 0, yh2 = 1
With uh = (xh1−xh2) denoting the difference between treatments for the covariables
xhi within a pair, a vector fh = (dh,u
′
h)
′ can be formed for each pair h. The respective
fh are statistically independent on the basis of (1) the respective pairs being comparable
to a random sample from a relevant target population and (2) the independent random
allocation of the two treatments within corresponding pairs. The mean vector f¯ =
(d¯, u¯′)′ = 1
q
∑q
h=1 fh can be formed with an unbiased estimate for its covariance matrix
Vf¯ as shown in (2.1). Here, d¯ represents the unadjusted difference in proportions of
success between the treatments.
Vf¯ =
1
q(q − 1)
q∑
h=1
(fh − f¯)(fh − f¯)′ =
 vd¯ V ′d¯,u¯
V d¯,u¯ Vu¯
 (2.1)
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A covariate-adjusted estimate of the difference in proportions of successes on the treat-
ments can then be obtained using weighted least squares methodology by forcing the
difference in means for the covariables to zero. With adjustment for P covariables,
the model Z = (1 0′P )
′ can be fit to f¯ , where 0P is a zero vector of length P . The
covariate-adjusted estimate b for the difference in proportions is given in (2.2).
b = (Z ′V −1
f¯
Z)−1Z ′V −1
f¯
f¯
= (d¯− V ′d¯,u¯V −1u¯ u¯)
=
q∑
h=1
(dh − V ′d¯,u¯V −1u¯ uh)/q
(2.2)
A consistent estimator for the variance of b is Vb in (2.3).
Vb = (Z
′Vf¯
−1Z)−1
= (vd¯ − V ′d¯,u¯V −1u¯ V d¯,u¯)
=
q∑
h=1
(
(dh − d¯)− V ′d¯,u¯V −1u¯ (uh − u¯)
)2
/q(q − 1)
(2.3)
where vd¯, V d¯,u¯, and V u¯ are the sub-matrices of V f¯ that correspond to the variance of
d¯, the covariance vector of d¯ with u¯, and the covariance matrix of u¯, respectively. The
estimator b has an approximate normal distribution when the number of matched pairs
q is sufficiently large such that f¯ has an approximately multivariate normal distribution.
Where n1 and n−1 represent the number of pairs with dh = 1 and the number of pairs
with dh = −1, min(n1, n−1)/(P + 1) should be ≥ 8 and, ideally, ≥ 10. It follows
that the statistic b2/Vb has an asymptotic chi-squared distribution with one degree of
freedom. A 100∗(1−α)% confidence interval for b may be obtained as b± z1−α/2 ∗
√
Vb
where z1−α/2 is the 100∗(1−α/2)th percentile of a standard normal distribution. When
q is only moderately large (e.g., 25 ≤ q ≤ 60), the t-distribution with (q − q0 − 1− P )
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degrees of freedom (where q0 is the number of pairs with dh = 0) would improve the
approximate basis of this confidence interval.
Under the null hypothesis of no treatment difference whereby each individual in a
pair has the same response regardless of treatment assignment, the exact distribution
for f¯ has 2(q−q0) possible realizations, and the corresponding exact covariance matrix
Vf¯ ,0 has the form in (2.4).
Vf¯ ,0 =
1
q2
q∑
h=1
fhf
′
h
=
 vd¯,0 V ′d¯,u¯,0
V d¯,u¯,0 V u¯,0
 (2.4)
One then obtains the estimate b0 = (Z
′V −1
f¯ ,0
Z)−1Z ′V −1
f¯ ,0
f¯ , an estimator of its variance
Vb,0 = (Z
′Vf¯ ,0
−1Z)−1, and Qb,0 = b20/Vb,0 for each of N re-randomizations of the
treatment assignment. The proportion of the N re-randomizations with Qb,0 greater
than or equal to the observed Qb,0 would be the essentially exact p-value. Due to
computational feasibility, choosing N to be sufficiently large for appropriate precision
(e.g., N = 100, 000) may be a necessary Monte Carlo alternative to computing Qb,0 for
all 2q possible treatment assignments so that the standard error of p is about 0.0005
for one-sided p-values that are near or below 0.025.
Since Vf¯ ,0 is constant for all 2
q possible treatment assignments, one could compare
each b0 from the N re-randomizations to the observed b0 instead of using Qb,0 to obtain
the exact p-value; the result will be identical. The exact analysis can be conducted
using a procedure such as PROC MULTTEST in SAS software (SAS Institute, Cary,
NC). However, it is important to note that when using the variance Vf¯ ,0 in (2.4), a
trade-off is that the formal inference is restricted to the randomized study population,
and so broader generalization is informal. This posture is in contrast to the variance
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Vf¯ in (2.1) which assumes generalizability through pairs being like a random sample
of pairs from a corresponding population.
This methodology relies upon the assumption of a valid randomization, under which
no differences between the means of the covariables are expected between the two
treatment groups. Random imbalances in these means between the two groups can be
assessed with the statistic
Qu¯ = (f¯ −Zb)′Vf¯−1(f¯ −Zb) (2.5)
For sufficiently large q, this statistic approximately has the chi-squared distribution
with P degrees of freedom, and its counterpart Qu¯,0 with b0 and Vf¯ ,0 replacing b and
Vf¯ can have exact assessment.
2.2.2 Informative 1:1 Matched Sets for Odds Ratio
If the assumption of similar covariate distributions in the treatment groups remains
applicable when non-informative pairs with dh = 0 are removed from the analysis,
other analysis approaches may be justifiable. Consider ah,I for informative pairs, where
ah,I = 1 if Treatment 1 is a success and Treatment 2 is a failure and ah,I = 0 if
Treatment 1 is a failure and Treatment 2 is a success. Also, ah,I is considered missing
when the same outcome is observed for Treatment 1 and Treatment 2 within a pair,
and such non-informative pairs h with missing ah,I are omitted from the analysis. With
zh,I = (ah,I ,u
′
h,I)
′, z¯I = (a¯I , u¯′I)
′ = 1
q′
∑q′
h=1 zh,I , and Vz¯I formed in a similar manner as
Vf¯ in (2.1), the model Z = (1 0
′
P )
′ can be fit to z¯I . Here, a¯I represents the proportion
of pairs (among q′ = (q−q0) informative pairs) with success on Treatment 1 and failure
on Treatment 2. An estimate bI = (Z
′V −1z¯I Z)
−1Z ′V −1z¯I z¯I can be obtained via weighted
least squares with consistent variance estimator VbI = (Z
′Vz¯I
−1Z)−1. An associated
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matched pairs odds ratio for the treatment effect is bI/(1 − bI), with 100∗(1 − α)%
confidence interval (bI,L/(1− bI,L), bI,U/(1− bI,U)) where bI,L = bI − z1−α/2 ∗
√
VbI and
bI,U = bI + z1−α/2 ∗
√
VbI .
Analysis may also proceed on dh,I for the informative pairs where dh,I = 1 if Treat-
ment 1 is a success and Treatment 2 is a failure, and dh,I = −1 if Treatment 1 is a
failure and Treatment 2 is a success. Then d¯I represents the difference in the proportion
of pairs with Success/Failure and the proportion of pairs with Failure/Success. With
a covariate-adjusted counterpart b∗I of the difference in proportions d¯I and variance
estimator Vb∗I using the dh,I , the matched pairs odds ratio is (b
∗
I + 1)/(1 − b∗I) with
100∗(1 − α)% confidence interval ((b∗I,L + 1)/(1 − b∗I,L), (b∗I,U + 1)/(1 − b∗I,U)). Exact
analysis can proceed in this setting as previously described using the variance under
the null hypothesis in (2.6) where fh,I = (dh,I ,u
′
h,I)
′.
V f¯I,0 =
1
(q′)2
q′∑
h=1
fh,If
′
h,I (2.6)
Alternatively, one can include all the pairs in the analysis by forming ah1 and ah2,
where ah1 = 1 if dh = 1 (0 else), and ah2 = 1 if dh = −1 (0 else). The vector
gh = (ah1, ah2,u
′
h)
′ can be created, and the associated mean vector g¯ = (a¯1, a¯2, u¯′)′
and estimated covariance matrix Vg¯ can be formed in ways comparable to f¯ and Vf¯ .
A transformation (via Taylor series linearization) may then be applied such that the
model Z = (1 0′P )
′ can be fit to ˜¯g = (loge(a¯1/a¯2), u¯′)′ using the transformed covariance
matrix V˜¯g = AVg¯A
′, where
A =
 1a¯1 −1a¯2 01×P
0P×1 0P×1 IP×P

and where 0P×1 is a matrix of zeroes and IP×P is a P × P identity matrix. Then
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b˜ = (Z ′V −1˜¯g Z)
−1Z ′V −1˜¯g ˜¯g represents the adjusted estimate of the log of the matched
pairs odds ratio and a consistent estimator for the variance of b˜ is Vb˜ = (Z
′V˜¯g
−1Z)−1. A
large-sample 100∗(1−α)% confidence interval can be obtained for the log odds ratio as
b˜±z1−α/2 ∗
√
Vb˜. This approach retains the covariate information from non-informative
pairs so that similar covariate distributions in the treatment groups holds on the basis
of a valid randomization.
An alternative to Taylor series linearization for obtaining a confidence interval for
the odds ratio is Fieller’s theorem (Fieller, 1954). Since the matched pairs odds ratio
can be expressed as the ratio of two means, a¯1/a¯2, this approach is applicable. Using
the vector g¯ and its covariance matrix Vg¯, one obtains the covariate-adjusted estimates
b˜ = (b˜1, b˜2)
′ and its associated covariance matrix Vb˜ through weighted least squares.
One then forms the adjusted matched pairs odds ratio as b˜1/b˜2, and the confidence
limits are the solutions x of a quadratic equation ax2 + bx+ c = 0 where a, b, and c are
as follows:
a = b˜22 − z21−α/2 ∗ (vb˜2)
b = 2 ∗ [z21−α/2 ∗ (vb˜1,b˜2)− b˜1 ∗ b˜2]
c = b˜21 − z21−α/2 ∗ (vb˜1)
(2.7)
Here, vb˜2 and vb˜1 are estimated variances of b˜2 and b˜1, respectively, and vb˜1,b˜2 is their
estimated covariance obtained from Vb˜. The quantity z
2
1−α/2 = 3.84 in the case of a
95% confidence interval.
2.2.3 M :1 Matched Sets with Randomization
The methodology in Section 2.2.1 may readily be extended to M :1 matched sets with
randomization. These types of sets may arise in randomized clinical trials where one
patient is randomized to control and M patients are randomized to the test treatment
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within the matched set. In practice, M usually ranges between two and four.
Assume, without loss of generality, that we have M :1 matched sets where M patients
are randomized to Treatment 1 and one patient is randomized to Treatment 2. Let
yhik = 1 denote a success for patient k on the ith treatment (i = 1, 2) from set h
(h = 1, . . . , q), and let yhik = 0 denote a failure for patient k on the ith treatment from
set h. Here, k = 1, . . . ,M if i = 1, and k = 1 if i = 2. Let y¯h1· = 1M
∑M
k=1 yh1k be the
proportion of successes for the M patients on Treatment 1 in set h. Additionally, let
xhik be the vector of covariates corresponding to the ith treatment for patient k from
set h, and x¯h1· = 1M
∑M
k=1 xh1k is the mean vector of covariates for the M patients on
Treatment 1 from set h. A vector of the differences in outcomes for the two treatments
can be formed as dh = (y¯h1· − yh21). With uh = (x¯h1· − xh21) denoting the difference
between treatments for the means of the covariables within a set, a vector fh = (dh,u
′
h)
′
can be formed for each set h. The mean vector f¯ = (d¯, u¯′)′ = 1
q
∑q
h=1 fh can be formed
with an estimated covariance matrix Vf¯ similar to (2.1). A covariate-adjusted estimate
of the difference in proportions for the treatments can then be obtained in a similar
manner using weighted least squares methodology to obtain b as in (2.2) and Vb as
in (2.3). Random imbalances in the means of the covariables between the treatment
groups can be assessed using the statistic in (2.5).
Methodology for obtaining an exact p-value for the treatment comparison would
proceed in a similar manner to the methods described in Section 2.2.1 with the use of
Vf¯ ,0 instead of Vf¯ . Under the null hypothesis that the response of each of the M + 1
members of each set would be the same regardless of treatment assignment, Vf¯ ,0 would
take the form in (2.7). As previously stated, exact inference would then be formally
restricted to the randomized study population.
Vf¯ ,0 =
(M + 1)
M2q2
q∑
h=1
2∑
i=1
nhi∑
k=1
(ghik − g¯h)(ghik − g¯h)′ (2.7)
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Here, nh1 = M , nh2 = 1, and ghik = (yhik,x
′
hik)
′ denotes the compound vector of
the response and covariates for the kth individual on the ith treatment from the hth
matched set. Additionally, the mean of this vector for the the hth matched set is given
as g¯h =
1
M+1
∑2
i=1
∑nhi
k=1 ghik. The formula (2.7) takes into account the M + 1 possible
ways to assign M individuals to Treatment 1 and one individual to Treatment 2. When
M = 1, the formula reduces to the form in (2.4).
A covariate-adjusted odds ratio may also be obtained for the M :1 setting. The
procedure begins with an unadjusted estimate of the odds ratio such as the Mantel-
Haenszel estimate (Breslow and Day, 1980), (Mantel and Haenszel, 1959) as in (2.8).
ψˆmh =
∑M
m=0mnm,0∑M
m=0(M −m)nm,1
(2.8)
Here, nm,1 is the number of matched sets with m successes among the M subjects
on test treatment and one success on control, and nm,0 is the number of matched sets
with m successes on test treatment and zero successes on control. One could also
define ah1 = m if there are m successes on test treatment when there is a failure on
control (m = 0, . . . ,M) for matched set h, and define ah1 = 0 if there is success on
control. Similarly, define ah2 = M −m if there are m successes on test treatment when
there is a success on control, and define ah2 = 0 if there is failure on control. Then∑q
h=1 ah1 equals the numerator of ψˆmh and
∑q
h=1 ah2 equals the denominator of ψˆmh.
A vector gh = (ah1, ah2,u
′
h)
′ can be formed. Its mean vector g¯ and covariance matrix
Vg¯ are formed as in Section 2.2.1. Covariate adjustment may then proceed through the
application of weighted least squares to the transformed vector ˜¯g = (loge(a¯1/a¯2), u¯
′)′ =
(loge(ψˆmh), u¯
′)′ using its transformed covariance matrix. Construction of a large-sample
confidence interval for the log odds ratio could proceed based on the covariate-adjusted
estimate b˜ and its estimated variance vb˜ as in Section 2.2.1. Alternatively, the covariate-
adjusted estimate b˜ = (b˜1, b˜2)
′ and its variance matrix Vb˜ could be estimated from
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weighted least squares using g¯ and Vg¯, and Fieller’s theorem is then applied to create
a confidence interval for the ratio b˜1/b˜2.
2.2.4 1:1 Matched Case-Control Studies
Matched sets often arise in non-randomized case-control studies where interest lies
in assessing the relationship between a dichotomous exposure (Yes/No) and case-control
status. The mechanism of NPANCOVA can be applied to a 1:1 matched case-control
study as follows: Define yh1 = 1 if the case from pair h was exposed and yh1 = 0 if
that case was not exposed. Similarly, define yh2 = 1 if the control from pair h was
exposed and yh2 = 0 if not exposed. Let xh1 be the covariates for a case, and let xh2
be the covariates for a control. It should be noted that in the case-control setting, the
difference in the means of covariables defined by case-control status is not likely zero
unless the covariables are not predictive of case-control status.
Consider dh = yh1(1 − yh2) − yh2(1 − yh1). Then dh = 1 if the case from pair h
is exposed and the control from pair h is not, dh = 0 if the case and control have
the same exposure status, and dh = −1 if the control is exposed and the case is not.
Further define ch = yh1(1 − yh2)(xh1 − xh2) + yh2(1 − yh1)(xh2 − xh1). Note that
ch = dh(xh1 − xh2). Thus, when the case is exposed and the control is not exposed in
pair h, ch represents the difference in the covariables of exposed and unexposed. When
the control is exposed and the case is not exposed in pair h, ch represents the difference
in the covariables of exposed and unexposed as well.
The NPANCOVA methodology may then be applied to a vector fh = (dh, c
′
h)
′ as
in the setting with randomization. Use of ch ensures the difference in the means of
covariables will be defined by exposure status rather than case-control status, although
the analysis excludes sets where both the case and control within a pair are exposed
or both the case and control are not exposed (since fh would be a vector of zeros by
25
definition). The odds ratio and its confidence interval can be formed via the methodol-
ogy relating to the informative pairs analysis on the dh,I in Section 2.2.2, and pairs are
excluded when the dh = 0. The mean vector f¯ I is formed as before and Vf¯ I is created
as in (2.1). The covariate-adjusted estimate b∗I is formed as in (2.2) and its consistent
variance estimator Vb∗I is formed as in (2.3). It should be noted that while this odds
ratio is technically the exposure odds ratio, this quantity is algebraically equivalent
to the disease odds ratio of interest. Assessment of goodness-of-fit (in the sense of
comparable distributions of covariates for the exposure groups) may proceed using the
statistic in (2.5) using data for the informative pairs analysis.
2.3 Examples
2.3.1 Multi-Center 1:1 Clinical Trial Data for Improvement of
a Skin Condition
Researchers enrolled one pair of individuals from each of 79 randomly selected clin-
ics. For each pair, one individual was randomly chosen to receive the test treatment,
and another individual was randomly chosen to receive placebo. The initial grade of
a skin condition (coded 1-4 for mild to severe) was recorded for each patient. The
outcome of improvement in the skin condition was recorded as a 1 for improvement
and 0 for no improvement. A matched pairs analysis is appropriate for these data, with
adjustment for initial grade of the skin condition. Thirty-four (43%) pairs showed im-
provement for the patient receiving test treatment and no improvement for the patient
receiving placebo. Twenty (25%) pairs showed improvement for the placebo patient
but not the patient on test treatment. The remaining 25 (32%) pairs were concordant
(both members of a pair showed improvement or both showed no improvement). The
data are available in (Stokes, Davis and Koch, 2012).
Results are presented in Table 2.1. With no covariate adjustment, the difference
26
in proportions of individuals with improvement on test (but not placebo) and placebo
(but not test) was d = ((34/79)− (20/79)) = 0.1772 (S.E.=√vd=0.0909). With respect
to
√
vd,0 under the null hypothesis, the unadjusted McNemar’s test statistic d
2/vd,0
had p=0.0567 from its approximate chi-squared distribution with d.f.=1; and its exact
counterpart from McNemar’s test was 0.0759 via the EXACT MCNEM option in SAS
PROC FREQ. When covariate adjustment was made, the adjusted estimate of the
difference in proportions was 0.1930 with an associated 13% reduction in the standard
error (S.E.=0.0791). The treatment effect was found to be statistically significant via
Qb,0 = b
2
0/vb,0 with p=0.0181; the corresponding exact counterpart had p=0.0179 based
on N = 100, 000 re-randomizations for the NPANCOVA analysis. The approximate
two-sided 95% confidence interval for the difference in proportions from NPANCOVA
was (0.0380, 0.3480). An approximation using the t-distribution with (q−q0−1−P ) =
(79 − 25 − 1 − 1) = 52 degrees of freeom was (0.0343, 0.3517). No evidence of a
random imbalance in initial skin condition between the two treatment groups was found
(Qu¯ = 0.1181, df=1, p=0.7311).
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When only informative strata were considered in the analysis, the adjusted pro-
portion of individuals with a success on test treatment (and failure on placebo) was
0.6262. This was statistically different from 0.5 with a p-value of 0.0288. The odds of
success on test treatment (and failure on placebo) were (0.6262/0.3738)=1.6754 times
the odds of success on placebo (and failure on test). When considering the difference
in proportions for the informative pairs, the resulting odds ratio and p-value were iden-
tical, and the exact p-value was 0.0280. Among the informative strata, there was no
evidence of a random imbalance in initial skin condition between the two treatment
groups (Qu¯ = 0.0088, df=1, p=0.9251).
The unadjusted McNemar’s odds ratio was 34/20 = 1.7000, whereas when adjusting
for intial skin condition, conditional logistic regression produced an odds ratio of 2.0366,
and this estimate was statistically significant (p=0.0353). The NPANCOVA analysis
on all pairs produced an adjusted odds ratio (1.7842) similar to the McNemar’s odds
ratio, and a 13% reduction in the standard error for its logarithm (from the McNemar’s
S.E. of 0.2818) was observed (S.E.=0.2462). This resulted in a statistically significant
p-value for the treatment effect (p=0.0187). It should be noted that the estimated odds
ratio for NPANCOVA tends to be closer to the null of 1.0 than the conditional logistic
regression estimate because the NPANCOVA estimate is like a population-averaged
estimate relative to covariates for matched subjects, and the conditional logistic regres-
sion estimate has a subject-specific interpretation for matched patients with the same
initial skin condition.
The 95% large-sample confidence interval for the McNemar’s odds ratio was (0.9785,
2.9533), while a slightly more conservative interval using Fieller’s theorem (data not
shown) produced an interval of (0.9941, 3.1794). For the covariate-adjusted odds ra-
tio, the large-sample interval was (1.1012, 2.8909), and the interval based on Fieller’s
29
theorem was (1.1198, 3.0913). While the large-sample intervals were based on esti-
mates where the log odds ratio was first created then underwent covariate adjustment,
the Fieller’s theorem intervals were based on creating a ratio of the covariate-adjusted
means. In the unadjusted case, the estimated matched pairs odds ratio was 1.7 re-
gardless of method. For the adjusted case, the different approaches produced similar
estimated odds ratios (1.7842 for NPANCOVA, 1.7846 for ratio of adjusted means).
2.3.2 Extension of Multi-Center Clinical Trial Data to 2:1 Set-
ting
To illustrate the application of the NPANCOVA methodology to a randomized
clinical trial with 2:1 matching, the data from Example 2.3.1 were re-examined. The
54 informative pairs and the 25 non-informative pairs were ordered separately by the
average baseline age for a pair. Starting with the smallest average baseline age, the
first non-informative pair was divided so that the patient on treatment was assigned
to treatment for the first informative pair, and the patient on placebo was assigned
to placebo for the second informative pair. The next non-informative pair on the
list was divided so that the patient on placebo was assigned to placebo for the third
informative pair, and the patient on treatment was assigned to treatment for the fourth
informative pair. This procedure continued (with the division of the 53rd informative
pair and deletion of the 54th informative pair) until 26 2:1 sets and 26 1:2 sets were
created. Since age had essentially no association with the response (within pairs), this
assignment was essentially random and kept all but one of the original pairs in the
analysis data set.
Since the data contain matched sets of different type (e.g. 2:1 and 1:2), a stratified
application of NPANCOVA was warranted (Koch et al., 1998). The vectors d¯1 and u¯1
were formed for the 2:1 sets, and d¯2 and u¯2 were formed for the 1:2 sets as in Section
30
2.2.1. Separate f¯ 1 and f¯ 2 vectors and covariance matrices Vf¯1 and Vf¯2 were also
formed as appropriate. A weighted estimate f¯w = (q1f¯ 1 +q2f¯ 2)/(q1 +q2) and weighted
covariance matrix Vf¯w = (q
2
1Vf¯1 + q
2
2Vf¯2)/(q1 + q2)
2 were created, where q1 = 26 and
q2 = 26 were the numbers of 2:1 and 1:2 sets, respectively. Weighted least squares was
then applied to f¯w using Vf¯w to obtain an estimate adjusted for initial skin condition. If
the number of matched sets for each type of allocation was ≥ 50, covariate adjustment
could have been applied to the 2:1 sets and 1:2 sets separately before weighting the
estimates across type of matched set.
A stratified version of the methodology for the odds ratio can be applied in a similar
manner. For the 2:1 sets, the procedure for obtaining the estimate and its covariance
matrix is as described in Section 2.2.3. For the 1:2 sets, ah1 = 2, 1, or 0 if 0,1, or 2
placebo successes were observed in set h when a test success was observed and is 0
if a test failure was observed, and ah2 = 0, 1, or 2 if 0,1, or 2 placebo successes were
observed in set h when a failure on test was observed and is 0 if a test success was
observed. A vector g¯j = (a¯1j, a¯2j, u¯
′
j)
′ was formed for each type of allocation so that
j = 1 for the 2:1 sets and j = 2 for the 1:2 sets. Corresponding covariance matrices
Vg¯j (j = 1, 2) can be formed through the expression in (2.1). A weighted vector
g¯w = (a¯1w, a¯2w, u¯
′
w)
′ and its covariance matrix Vg¯w are then formed as above. Then
the Mantel-Haenszel estimate of the log of the odds ratio for test vs. placebo would
be given as loge(a¯1w/a¯2w) and covariate adjustment could proceed via weighted least
squares with the vector ˜¯gw = (loge(a¯1w/a¯2w), u¯
′
w)
′, covariance matrix V˜¯gw = AVg¯wA
′,
and model Z = (1 0′P )
′.
Results are presented in Table 2.2. The unadjusted difference in proportions be-
tween the test and placebo groups was 0.1923 (S.E.=0.1084). At the 0.05 level, this
result was not significantly different from zero with p=0.0761. However, with respect to
the null variance from (2.7) with weighting across the strata (S.E.=0.0981), p=0.0499,
31
with this being identical to the Mantel-Haenszel p-value from SAS PROC FREQ. When
adjusting for initial skin condition, the difference in proportions for NPANCOVA using
the variance form in (2.1) weighted across the strata was 0.2087 (S.E.=0.0865). This
was statistically significant with a p-value of 0.0158. The assessment for random imbal-
ances in mean initial skin condition between the two treatment groups had Qu¯ = 0.0632
with df=1 and p=0.8015, indicating no evidence of an imbalanced randomization with
respect to initial skin condition.
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1 Test : 2 Placebo
Placebo
0 1 2
Test 1 4 14 0
0 0 3 5
2 Test : 1 Placebo
Placebo
0 1
2 12 0
Test 1 3 6
0 0 5
Figure 2.1: Frequencies of Success Outcomes for Treatment (T) * Placebo (P) for 1:2
and 2:1 Matched Sets for Data from Example 2.3.2
Regarding the odds ratio, consider the data in Figure 2.1. When considering the 1:2
matched sets, the unadjusted M-H estimate of the odds ratio is ψˆmh = (2(4) + 1(14) +
0(0))/(0(0) + 1(3) + 2(5)) = 1.6923. For the 2:1 matched sets, the unadjusted M-H
estimate of the odds ratio is ψˆmh = (0(0) + 1(3) + 2(12))/(2(5) + 1(6) + 0(0)) = 1.6875.
Table 2.2 contains the estimate of the odds ratio after combining the 1:2 and 2:1
estimates. The unadjusted odds ratio is the ratio of the sum of the numerators in the
1:2 and 2:1 estimates divided by the sum of the denominators and was (8 + 14 + 3 +
24)/(3 + 10 + 10 + 6) = 49/29 = 1.6897.
The NPANCOVA analysis produced an odds ratio of 1.7701, indicating that the
odds of improvement on test treatment are roughly 1.8 times the odds of improve-
ment on placebo after adjusting for initial skin condition. This odds ratio is closer
to the null than the odds ratio obtained from conditional logistic regression (2.0637),
which is expected given the NPANCOVA odds ratio is a population-averaged estimate
(relative to covariates) for matched subjects; the odds ratio from conditional logistic
regression is subject-specific with respect to matched patients with the same initial skin
condition. A 20% reduction in the standard error for the log odds ratio was observed
(S.E.=0.2478) as compared to the unadjusted analysis (S.E.=0.3093). The p-value
for the unadjusted analysis was not significant (p=0.0899) at the 0.05 level, but the
p-values for the NPANCOVA analysis (p=0.0212) and conditional logistic regression
34
(p=0.0287) were statistically significant.
A 95% confidence interval for the unadjusted odds ratio was (0.9215, 3.0980), and
an interval based on Fieller’s theorem (data not shown) was (0.9475, 3.3624). The
estimated odds ratio for the unadjusted case is 1.6897, and in the case of Fieller’s, the
ratio of unadjusted means was also estimated as 1.6897. After covariate adjustment,
the large-sample confidence interval was (1.0891, 2.8770) with an odds ratio estimate
of 1.7701. Using Fieller’s theorem, the confidence interval was (1.1103, 3.0629) with
the ratio of covariate-adjusted means being 1.7706.
2.3.3 1:1 Matched Case-Control Study of Vaccine Exposure
and Influenza
Researchers tracked cases of influenza requiring hospitalization in residents of a mid-
western county, aged 65 and older during a two-month period in one winter. Each case
was sex- and age-matched to two controls, and information was obtained on whether
study participants had a vaccine shot and whether they had lung disease. The data for
these 150 matched sets are available in (Stokes, Davis and Koch, 2012). For illustra-
tion, the data from each case was duplicated and then separately assigned to each of
the two controls within a set to create 300 case-control pairs matched on the basis of
sex and age.
Results are presented in Table 2.3. When considering only the informative pairs
(145 matched pairs), the unadjusted analysis produced a log odds ratio of -0.3199
(S.E.=0.1688). This was not statistically significant at the 0.05 level (p=0.0580). A
4.9% reduction in the standard error was observed with the NPANCOVA adjusted anal-
ysis of the log odds ratio (S.E.=0.1605). The odds ratio for NPANCOVA was 0.7214,
and the p-value was p=0.0420. The conditional logistic regression analysis produced
an adjusted log odds ratio of -0.3616 (S.E.=0.1781). Thus, the odds of being a case for
35
vaccinated individuals compared to unvaccinated individuals was exp(-0.3616)=0.6966,
after adjusting for lung disease and matched set. Statistical significance was similarly
observed at the 0.05 level with p=0.0409. For NPANCOVA, the test of goodness-of-
fit (in the sense of similar proportions of patients with lung disease in the vaccinated
and unvaccinated groups) was not contradictory (Qu¯ = 0.0158, df=1, p=0.9001). As
in Example 2.3.1, the adjusted odds ratio for NPANCOVA tends to be closer to the
null value of 1.0 than the estimate from conditional logistic regression since it has an
interpretation as a population-averaged estimate (relative to covariates) for matched
subjects, and the estimate from conditional logistic regression has an interpretation as
an estimate which is applied to matched subjects with the same status for lung disease.
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2.4 Discussion
This chapter outlines methodology for applying nonparametric randomization-based
analysis of covariance to dichotomous outcomes from matched sets with very small sam-
ple sizes within the matched sets. The methods presented here are an alternative to
McNemar’s test in the case of matched pairs or conditional logistic regression when
covariate adjustment is desired. NPANCOVA only requires a valid randomization to
the two treatment groups as well as large enough sample size so that weighted least
squares estimates have approximate multivariate normal distributions. However, exact
inference for testing null hypotheses may be performed for the permutation distribu-
tions of the weighted least squares estimates. In the case of an observational matched
case-control study, the NPANCOVA methodology is applicable to informative pairs
provided the distributions of the covariables are similar by exposure status. For the
1:1 randomized trial and 2:1 randomized trial examples, variance reduction was ob-
tained after covariance adjustment with NPANCOVA (as compared to the unadjusted
analyses). In the 1:1 matched case-control study, variance reduction was observed as
compared to the unadjusted analysis.
The NPANCOVA methods presented here are appropriate for the regulatory setting
where statistical assumptions of parametric modeling methods can not be verified prior
to the collection of data. Conditional logistic regression methods for matched sets make
assumptions about the relationship between the log odds of response and covariates.
Additionally, standard errors for the treatment effect in a conditional logistic regression
model may not necessarily decrease with covariance adjustment. It has been observed
that the increase in standard error may be accompanied by an increase in the esti-
mated treatment effect, which may provide a p-value that is comparable to the p-value
obtained from NPANCOVA (Tangen and Koch, 1999a). The NPANCOVA methods
presented here avoid any modeling assumptions about the relationship between the
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outcomes and covariables for adjustment, and standard errors for the treatment effect
estimates do not increase as a consequence of adjustment.
The methodology which restricts analysis to only informative pairs makes an as-
sumption that the distributions of the covariates remain similar between treatment
groups after the removal of non-informative pairs. In the case of the 1:1 matched case-
control study, the assumption is that the exposure groups have similar distributions
of adjustment covariables. The estimated treatment effect may be subject to bias if
this assumption does not hold, as forcing the differences in means of covariables to
zero may no longer be appropriate. Assessment of goodness-of-fit of the weighted least
squares model can be done through the statistic in (2.5). In the 1:1 randomized case,
we offer the methodology which includes all pairs as a way of avoiding this assumption
about non-informative pairs. For the matched case-control study, the assumption may
be reasonable if the influence of unobserved covariates is thought to be negligible after
matching and covariate adjustment for potential confounders.
The methods presented in this chapter are intended for application to matched pairs
and matched sets of size ≤ 10. For studies with matched sets of larger size, methodology
in the next chapter may be more easily implemented. The methodology involves using
the DFBETA diagnostics from a treatment-only conditional logistic regression model to
estimate the covariance of the unadjusted log odds ratio. Ths covariance estimate can
then be combined with information relating to the covariance matrix for the differences
in means of covariables in order to produce a covariate-adjusted estimate of the log
odds ratio via weighted least squares. This approach is also extended to time-to-event
outcomes in the presence of stratification.
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Chapter 3
Nonparametric
Randomization-Based Covariate
Adjustment for Stratified Analysis
of Time-to-Event or Dichotomous
Outcomes
3.1 Introduction
For studies which have matched sets and dichotomous outcomes, conditional logistic
regression is an analysis method which is often used in order to estimate odds ratios
while adjusting for other covariables. Adjusting for the strata formed by the matched
sets could be done through indicator variables in an unconditional logistic regression,
but bias in model fitting can become an issue if the number of terms in the model is
large relative to the available sample size, or the sample size per stratum is small (e.g.
< 10) for some strata (Breslow and Day, 1980). Thus, conditional logistic regression is
a method which removes the variability among the strata and results in estimation of
relationships for explanatory variables with variation within strata. Maximum likeli-
hood estimates of odds ratios can be obtained via maximizing a conditional likelihood.
This conditional likelihood is formed by conditioning on sufficient statistics for the
strata-specific intercepts in the model. This results in a regression model which elim-
inates those extra parameters and provides an estimated effect for treatment or other
covariates. However, the use of a conditional likelihood means no individual stratum
effects can be estimated; they are considered nuisance parameters.
Stratification may also be accommodated in studies where the outcome is a time-
to-event outcome. The Cox proportional hazards model (Cox, 1972) is frequently used
for analyzing time-to-event outcomes in the presence of covariables. This is a model for
the hazard of the event, and it consists of the product of two parts. The first relates to
the underlying baseline hazard, which is not assumed to have any particular functional
form. The second part relates to the covariables, and it consists of the exponentiation of
a linear combination of P covariables with parameters β = (β1, . . . , βP )
′. The net effect
of a one-unit increase in the jth covariate corresponds to a multiplicative increase of
exp(βj) in the hazard of the event. A stratified analysis may be conducted with the Cox
model by assuming separate baseline hazard functions for each level of a stratification
factor. This type of analysis may be reasonable if factors such as center (in a multi-
center clinical trial) or geographic region are thought to have heterogeneity in the
underlying baseline hazard with estimation of hazard ratios for these factors being not
of interest.
For both the conditional logistic regression model for dichotomous outcomes and
the proportional hazards model for time-to-event outcomes, regression diagnostics can
be used to assess the fit of the model. One diagnostic, the DFBETA residual, is calcu-
lated for each regression parameter for each independent observation in the data set.
Its value corresponds to the absolute change in the estimated regression parameter for
the full data set and the estimated regression parameter for the data set with that
observation omitted. For most applications, including the ones presented in this chap-
ter, the DFBETA residual is approximated via a one-step procedure. This involves
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starting at the estimated regression parameter for the full data set, deleting an obser-
vation, and making one more Newton-Raphson step to obtain the estimated regression
parameter with that observation omitted (Pregibon, 1981). Large values of DFBETA
imply stronger influence of a particular observation on the parameter estimates. These
diagnostics have been developed for unconditional logistic regression (Pregibon, 1981),
conditional logistic regression (Storer and Crowley, 1985), proportional hazards models
(Cain and Lange, 1984), and for generalized estimating equations (Preisser and Qaqish,
1996). Wei et. al. developed methodology for a robust estimate of the covariance ma-
trix of βˆ by using the sum (over the observations) of the cross-products of DFBETA
residuals (Wei, Lin and Weissfeld, 1989). This approach also applies to multivariate
time-to-event outcomes, and the DFBETA residuals can easily be obtained from the
PHREG procedure in SAS software.
In Section 1.5, methodology was described for applying nonparametric covariance
adjustment to an unadjusted log hazard ratio in a randomized clinical trial with a
time-to-event outcome and two treatment groups (Saville and Koch, 2013). A Cox
proportional hazards model was fit with a single indicator for treatment, and the asso-
ciated log hazard ratio β was estimated. Additionally, through the methodology of Wei
et. al., the sum of the squared DFBETAs from this model were used to obtain a robust
covariance estimate vβˆ (Wei, Lin and Weissfeld, 1989). Once these quantities were
obtained, they were combined with covariate information, and weighted least squares
was then used to adjust βˆ for the covariates.
This chapter extends the methodology of Saville and Koch (2013) to situations in-
volving stratification. In the case of a dichotomous outcome with matched sets, the
DFBETA residuals are obtained from a treatment-only conditional logistic regression
model. In the case of a stratified time-to-event analysis, the DFBETA residuals are
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obtained from a treatment-only Cox proportional hazards model which addresses pos-
sibly different baseline hazard functions for each stratum. Covariance structure for the
stratification adjusted log odds ratio (or hazard ratio) is estimated through the meth-
ods of Wei et. al.. Covariance matrices for the covariates are derived through methods
from Saville and Koch (2013) which produce a covariance matrix analogous to one pre-
sented in Koch et. al. (1998). Estimates of the corresponding covariances between the
respective log hazard ratio(s) and the respective differences in means of covariables are
provided through the sums of the cross-products of the DFBETA residuals with the
quantities derived from averages of pairwise differences in covariables for the respec-
tive individuals versus all individuals in the opposite treatment group. The appendices
present other specifications of the covariance structure derived from multivariate U-
statistics methods. The information from the treatment-only model and the covariance
matrix for the covariates is combined to provide nonparametric covariance adjustment
of the log odds ratio (or log hazard ratio) via weighted least squares. This approach
provides covariate adjustment which relies only on a valid stratified randomization and
does not make any assumptions about the relationships between the covariables and
the outcome. Methodology is first presented separately for the log odds ratio and the
log hazard ratio followed by examples and discussion.
3.2 Methods
3.2.1 Hybrid Methodology for Dichotomous Outcomes with
Stratification
Let pihj denote the probability of an outcome of interest for the jth individual
(j = 1, . . . , nh) in the hth stratum (h = 1, . . . , q) who is receiving either the test
treatment or the control. Here, n =
∑q
h=1 nh represents the total number of individuals
being studied. Assume that individuals on the study were randomized within strata
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to either test treatment or a comparator (which may or may not be placebo). Let
xhj = 1 if test treatment was received and xhj = 0 if comparator was received. Then,
a conditional logistic regression model only including treatment can be written as
log(
pihj
1− pihj ) = αh + βxhj (3.1)
where the αh is a stratum-specific intercept, and β represents the log of the odds ratio
comparing the odds of the outcome for test treatment to the odds of the outcome
on comparator within a stratum. This model eliminates the variability among strata,
focusing instead on assessment of a treatment effect within strata.
Let i = 1, 2 index the test and comparator groups, respectively, and let rhi =
(rhi1, . . . , rhinhi)
′ be the nhi × 1 vector of unstandardized DFBETA residuals for the
nhi individuals on treatment i in stratum h so that r = (r
′
11, r
′
12, . . . , r
′
q1, r
′
q2)
′ is the
n× 1 vector of DFBETA residuals from fitting the treatment-only conditional logistic
regression model in (3.1) to all n =
∑q
h=1
∑2
i=1 nhi individuals in the trial. Furthermore,
let nh = nh1 +nh2 for stratum h and let W =
∑q
h=1(nh1nh2)/nh. Also define xhik as the
P × 1 vector of covariates for the kth individual on treatment i from stratum h, and
let X ′hi = (xhi1, . . . ,xhinhi) be a P × nhi matrix of the covariates for the individuals
on treatment i in stratum h. With x¯hi =
∑nhi
k=1 xhik/nhi representing the sample
mean vector of the covariates for treatment i from stratum h, the nhi × P matrix
Chi =
nh1nh2
nhW
√
nhi(nhi−1)
(Xhi − 1x¯′hi) can be created where 1 is a nhi × 1 vector of ones.
An unbiased estimate for the covariance matrix for the covariate means for treatment
i in stratum h is in (3.2).
V x¯hi =
(
nh1nh2
nhW
)2
(Xhi − 1x¯′hi)′(Xhi − 1x¯′hi)
nhi(nhi − 1)
= C ′hiChi
(3.2)
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With the (P + 1) × 1 vector f = (βˆ, g¯′)′ = (βˆ, (x¯1 − x¯2)′)′ containing the esti-
mated log odds ratio βˆ from the treatment-only conditional logistic regression model
and the weighted difference in means of the covariates g¯ = (x¯1 − x¯2), where x¯i =∑q
h=1(nh1nh2x¯hi)/W , a consistent estimator for the covariance matrix of f is provided
by Vf in (3.3).
Vf =
 r′r ∑qh=1(r′h1Ch1 − r′h2Ch2)∑q
h=1(C
′
h1rh1 −C ′h2rh2)
∑q
h=1
∑2
i=1C
′
hiChi

=
 vβˆ V ′βˆ,g¯
V βˆ,g¯ Vg¯

(3.3)
The quantity r′r is a robust estimate of the variance of the estimate βˆ for the stratified
log odds ratio (Wei, Lin and Weissfeld, 1989). The quantity V βˆ,g¯ =
∑q
h=1(C
′
h1rh1 −
C ′h2rh2) provides the estimated covariance matrix for βˆ and (x¯1−x¯2), and the quantity
Vg¯ =
∑q
h=1
∑2
i=1C
′
hiChi is an unbiased estimate for the covariance matrix for (x¯1−x¯2).
The covariance structure for the covariates presented here is similar to the structure
of V w in Appendix II of Koch et. al. with appropriate weighting across the strata,
and it is an unbiased estimate for the covariance structure under the assumption that
patients are like a simple random sample from a stratified population (Koch et al., 1998).
Two other specifications for the covariance matrix for f , V˜f and V¯f , are presented in
Appendices (A.1.1) and (A.2), respectively.
A covariate-adjusted estimate of β can then be obtained using weighted least squares
methodology by forcing the difference in means for the P covariables to zero. The model
Z = (1 0′P )
′ can be fit to f , where 0P is a zero vector of length P . The estimate of the
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log odds ratio which is adjusted for covariates and for strata is b given in (3.4)
b = (Z ′V −1f Z)
−1Z ′V −1f f
= βˆ − V ′
βˆ,g¯
V −1g¯ g¯
(3.4)
and a consistent estimator for the variance of b, Vb is in (3.5).
Vb = (Z
′V −1f Z)
−1
= vβˆ − V ′βˆ,g¯V −1g¯ V βˆ,g¯
(3.5)
The estimator b has an approximate normal distribution when each treatment group
has at least minimal sample sizes within each stratum (e.g. nhi ≥ 5) and at least
moderate overall sample size (e.g. ≥ 50) so that f has an approximately multivariate
normal distribution. This methodology relies upon the assumption of a valid stratified
randomization, under which no differences between the stratification adjusted means of
the covariables are expected between the two treatment groups. Random imbalances
in these means between the two groups can be assessed with the statistic Q0 in (3.6).
Q0 = (f −Zb)′V −1f (f −Zb) (3.6)
This statistic approximately has the chi-squared distribution with P degrees of freedom.
3.2.2 Hybrid Methodology for Time-to-Event Outcomes with
Stratification
Let Thj be the observed event time (or censoring time if no event) for the jth individ-
ual (j = 1, . . . , nh) from the hth stratum (h = 1, . . . , q). The stratified treatment-only
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Cox proportional hazards model for the hazard of an event at time t is given in (3.7).
λ(t;xhj) = λoh(t)exp(βxhj) (3.7)
Here, λoh(t) represents the underlying baseline hazard function for stratum h, and xhj
is an indicator of the test treatment (vs. comparator). As in the case for dichotomous
outcomes, the vector of DFBETA residuals r = (r1, . . . , rn)
′ can be obtained from the
model fitting on the n individuals. The DFBETA rj represents the absolute change in
the estimated log hazard ratio βˆ when the jth individual is removed from the analysis.
Through the methods of Wei et. al., a robust estimate of the variance of βˆ is provided
by the quantity r′r (Wei, Lin and Weissfeld, 1989). Thus, if g¯ = (x¯1 − x¯2) is defined
to be the weighted difference in means of the covariables, the quantities Vg¯ and V
′
βˆ,g¯
are used to estimate a covariance matrix Vf for the vector f = (βˆ, g¯
′) as in (3.3).
Weighted least squares then provides a covariate-adjusted estimate of β by forcing
the differences in the stratified means of the P covariables to zero using the model
Z = (1 0′P )
′. This estimate, which is also adjusted for the stratification factor, is
given as b = (Z ′V −1f Z)
−1Z ′V −1f f , and its estimated covariance matrix is given as
Vb = (Z
′V −1f Z)
−1. As previously noted for its counterpart in (3.4), the estimate
b approximately has a normal distribution when the sample sizes in each group are
large enough so that f has an approximately multivariate normal distribution. Also,
random imbalances in the covariable means between the two groups can be assessed
with the statistic Q0 = (f − Zb)′V −1f (f − Zb), and this statistic approximately has
the chi-squared distribution with P degrees of freedom.
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3.3 Examples
3.3.1 Dichotomous Outcome: Neurologic Disorder Data
Researchers observed 431 events on 959 patients randomized to one of four treatment
groups (placebo, 50 mg, 100 mg, 200 mg) for management of unfavorable outcomes for
an incurable neurologic disorder. The primary event of interest was defined as time until
progression of disease. Results of the main analysis of the data have been reported
elsewhere (Lacomblez et al., 1996). Tangen and Koch (1999) provide discussion of
implenting nonparametric randomization-based covariance adjustment to these data
using Wilcoxon or logrank scores. For implementation of the NPANCOVA methods
as they relate to dichotomous outcomes in this chapter, the primary outcome for this
analysis was the Yes/No outcome of whether a patient progressed by 12 months after
randomization. Tangen and Koch (2001) have discussion of dose-response relationships
using nonparametric randomization-based covariance adjustment for this dichotomized
outcome. Six patients who were censored prior to twelve months were managed as
progression-free survivors. The 100 mg and 200 mg treatment groups were pooled
(n=480) and compared to the placebo group (n=242). The 50 mg treatment group was
omitted from the analysis. Strata were created as the cross-classification of geographic
region and site of disease onset so as to create six strata.
A subset of six baseline covariates were chosen from a set of 24 candidate baseline
covariates on the basis of a stepwise conditional logistic regression model (stratifying on
geographic region, site of disease onset, and pooled treatment group: 100 mg + 200 mg
vs. placebo) with an entry criterion of p < 0.005. This method produced a set of covari-
ates predictive of having an event by 12 months in a manner independent of treatment
assignment. Selected baseline covariates included age, disease duration (years), weight,
and three additional continuous measures of neurologic and musculoskeletal function.
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The overall missingness percentage for these covariates was 1.55%, and mean values for
the covariates (over all 959 original patients) were imputed for these missing values.
Table 3.1: Progression by 12 Months for Patients with a Neurologic Disorder from
Example 3.3.1 who Received Test Treatment (100 mg or 200 mg) or Placebo
Disease Progression by 12 Months
Strata Treatment Yes (Row %) No Total
1 Test 48 (31.2) 106 154
Placebo 30 (37.5) 50 80
2 Test 24 (36.9) 41 65
Placebo 20 (57.1) 15 35
3 Test 18 (16.1) 94 112
Placebo 18 (32.1) 38 56
4 Test 19 (35.8) 34 53
Placebo 10 (40.0) 15 25
5 Test 16 (25.0) 48 64
Placebo 8 (25.0) 24 32
6 Test 4 (12.5) 28 32
Placebo 4 (28.6) 10 14
219 503 722
The counts and proportions of patients (by treatment and stratum) with disease
progression by 12 months is presented in Table 3.1. Strata 1, 4, and 5 appear to have
somewhat similar proportions of events between test treatment and placebo, but there
is a lower proportion of events for the test treatment (vs. placebo) in strata 2, 3, and
6.
Results of the analysis are presented in Table 3.2. The stratified analysis without
adjusting for covariates produced an odds ratio estimate of 0.6206, indicating the odds
of having disease progression by 12 months were about 38% smaller for those on test
treatment vs. placebo. This estimate had a corresponding p-value of 0.0057, indicating
statistical significance at the 0.05 level. After adjustment for the baseline covariates,
the NPANCOVA analysis showed a standard error reduction of 14.8% for the log odds
ratio over the stratified analysis (from 0.1725 to 0.1470). The NPANCOVA adjusted
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odds ratio estimate (0.5774) moved somewhat further away from the null than the
stratified estimate of 0.6206, but the two values were reasonably similar and represent
an odds ratio that is like a stratified population-averaged estimate. The NPANCOVA
odds ratio estimate was in between the stratified estimate and the conditional logistic
regression estimate (0.4579), but the larger standard error for the conditional logis-
tic regression estimate (0.2091) resulted in the two analyses having the same p-value
(0.0002). The conditional logistic regression estimate of 0.4579 was further away from
the null than the stratified or NPANCOVA estimates, and this is likely due to it being a
conditional estimate which is interpretable through the comparison of individuals who
share the same values of both the strata and the covariates. The assessment for ran-
dom imbalances in the covariate distributions had a p-value of 0.4106, and this p-value
did not contradict the similarity of the covariate distributions between the treatment
groups.
3.3.2 Time-to-Event Outcome: Neurologic Disorder Data
The data from Example 3.3.1 are reconsidered with application of NPANCOVA
methods to the time-to-event outcome of progression-free survival over the main follow-
up period of 18 months. The same six strata were used in the analysis, and the sample
sizes and number of events for the strata are presented in Table 3.3. For the Cox
regression, the Efron method for ties was used (Efron, 1977).
A subset of six baseline covariates were chosen from a set of 24 candidate baseline
covariates on the basis of a stepwise Cox proportional hazards model (stratifying on
geographic region, site of disease onset, and treatment) with an entry criterion of p <
0.005. This produced a set of covariates predictive of time to progression in a manner
independent of treatment assignment. Selected baseline covariates included age, disease
duration (years), and the same three additional continuous measures of neurologic and
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musculoskeletal function which were included for the analysis for the dichotomized
outcome in Example 3.3.1. While the baseline weight did not meet the criteria for entry
for the stepwise Cox model (p=0.0081 > 0.005), this variable was considered predictive
of the outcome and was included so that the same six covariates were considered for
both the dichotomized outcome and the time-to-event outcome.
Figure 3.1: Kaplan-Meier Estimates of Progression-Free Survival for Neurologic Data
from Example 3.3.2
Kaplan-Meier curves are displayed in Figure 3.1 for describing time to progression
for the pooled treatment (100 mg + 200 mg) vs. placebo. This unadjusted analysis
(with strata and covariables ignored) shows a separation of the survival curves, and this
is reflected in the p-value for the logrank test (p=0.0480) and Wilcoxon test (p=0.0263).
When considering the six strata representing geographic region/site of disease onset,
the stratified logrank test had p=0.0322.
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Table 3.4 displays results from stratified analyses and stratified analyses adjusted
for the six covariates. The stratified analysis using the Cox model-based variance is
provided for reference. The stratified analysis using the robust variance of Wei et. al.
produced a hazard ratio of 0.7808, while the NPANCOVA and Cox adjusted analyses
produced hazard ratios further away from the null (0.7392 and 0.6170, respectively).
The hazard ratio for the NPANCOVA adjusted analysis was reasonably similar to the
stratified analysis, as it is like a stratified population-averaged estimate. The hazard
ratio for the Cox adjusted analysis is more like a conditional estimate which compares
individuals from the different treatment groups who share the same values of the co-
variates and strata.
The p-value of 0.0316 from the stratified analysis was similar to the p-value from the
stratified logrank test (p=0.0322), indicating that the analysis which assumes propor-
tional hazards on the treatment variable produced similar results as the nonparametric
test. Adjustment for covariates via NPANCOVA resulted in a 18.2% reduction in the
standard error for the log hazard ratio, from 0.1151 (stratified) to 0.0942 (NPAN-
COVA). The standard error from the Cox model was larger than that of the stratified
analysis, but the stronger estimate of the log hazard ratio resulted in the smallest p-
value of < 0.0001. While the p-values for the stratified analysis and the NPANCOVA
analysis were both below a significance level of 0.05, the covariance adjustment pro-
vided a reduction in the standard error for the log hazard ratio and stronger evidence
of efficacy (through p=0.0013). The assessment of random imbalances in the covari-
ates had Q0 = 6.1131 with six degrees of freedom, and p=0.4106. This p-value did
not contradict the similarity of distributions in the covariates between the treatment
groups.
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3.3.3 Dichotomous Outcome: Osteoarthritis Data
This example uses data from a randomized crossover trial for osteoarthritis of the
hip or knee (Pincus, Koch and Sokka, 2001). Researchers randomized 227 patients to
receive either experimental treatment (A) in the first period followed by active control
(C) in the second period (or C followed by A), with washout in between periods. A
screening visit was conducted (Visit 1), followed by a 3-7 day washout period before
the randomization at the baseline visit (Visit 2). After six weeks of treatment (the
end of the first period, Visit 3), patients returned to have pain assessments. Patients
were given the option to continue to the second treatment period. If they consented,
a 3-7 day washout period occurred, followed by the second baseline visit (Visit 4)
where they received a six-week supply of the treatment they did not receive in the first
period. Pain assessments were conducted at the end of this six-week treatment period
(Visit 5). A questionnaire used to assess pain was the Western Ontario and McMaster
Universities Osteoarthritis Index (WOMAC). This questionnaire has 24 items with each
item being scored using the following Likert scale: 0=None, 1=Mild, 2=Moderate,
3=Severe, 4=Extreme. The WOMAC index is calculated as (sum of item scores)/96
(to produce an index range of 0-100) with higher values indicating worse pain.
For this example, only data from the screening visit (Visit 1), the baseline visit
(Visit 2), and the end of the first period (Visit 3) were considered. There were 218
patients who had available data from all three visits. Study site was used to form the
strata. The 218 patients included for analysis were enrolled at twelve study sites, and
the sample sizes for the strata are listed in Table 3.5. The continuous WOMAC outcome
was dichotomized as a variable which took the value 1 if the score was ≤ 25 at the end of
the first period (Visit 3) or 0 if the score was > 25 at the end of the first period. This cut
point was chosen to represent an index for an individual answering ’Mild’ for all 24 items
on the questionnaire. Adjustment variables for analysis of covariance included sex,
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continuous baseline age, continuous screening outcome score, and continuous baseline
outcome score. For the analyses, ten strata were used after pooling the 7, 6, and 3
patients from strata 1, 5, and 7, respectively.
Table 3.6 displays the results of the stratified analyses for the WOMAC dichot-
omized outcome. When considering the WOMAC scale, the stratified odds ratio com-
paring the odds of a WOMAC score ≤ 25 for the experimental treatment group to the
odds for the active control was 2.0026. After adjustment via NPANCOVA, the odds
ratio moved closer to the null with a value of 1.7044. Adjustment via conditional logis-
tic regression produced an estimated odds ratio of 2.1135, which was larger than the
stratified odds ratio and further from the null. Finally, adjustment for covariables and
strata as fixed effects in an unconditional logistic regression produced an odds ratio of
2.2122, which was the furthest from the null and may be reflecting bias due to some
sites having very small sample sizes. The odds ratio estimate for NPANCOVA is more
like a stratified population-averaged estimate of the odds ratio, whereas the estimates
from conditional or unconditional logistic regression reflect conditional estimates of the
odds ratio for comparing treatment groups for individuals from the same strata who
share the same values of the other covariates.
The standard error for the stratified log odds ratio for the WOMAC outcome was
0.2830. With adjustment via NPANCOVA, there was a 17.5% reduction in the standard
error to 0.2335. For the conditional and unconditional logistic regression models, the
standard errors increased over their counterparts without covariables, with values of
0.3436 and 0.3535, respectively. While the standard errors for these methods were larger
than the stratified approach, the estimated log odds ratios were larger and resulted in p-
values of 0.0276 and 0.0231. While the stratified and NPANCOVA p-values were smaller
at 0.0141 and 0.0224, respectively, all the p-values for this example were statistically
significant at the 0.05 level and indicated efficacy of the experimental treatment. The
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assessment of random imbalance of the covariates had Q0 = 1.1792 with four degrees
of freedom and had p=0.8815. This p-value did not contradict the distributions of the
covariates being similar between the two treatment groups.
3.4 Discussion
The hybrid methdology presented in this chapter is useful in a regulatory setting
where a conditional analysis with covariate adjustment is desired when analyzing a
dichotomous outcome, but the assumptions of a parametric regression model can not
be verified prior to data collection. While the procedure does make use of a parametric
treatment-only model, the score test for the hypothesis H0 : β = 0 in the treatment-only
conditional logistic regression model is essentially identical to the Mantel-Haenszel test
which only relies on a valid randomization. Thus, the hybrid methodology does not re-
quire additional modeling assumptions of conditional logistic regression such as correct
functional form for the covariates. The covariate-adjusted estimate of the treatment
effect which is produced by the hybrid methodology is a stratified population-averaged
estimate, in contrast with the conditional logistic regression estimate which is inter-
pretable as a treatment effect for individuals who share the same values of the strata
and the covariates. It is recommended that the hybrid methodology be used to obtain
an adjusted treatment effect for the primary analysis. Subsequent assessment of inter-
actions or subgroup differences could be performed via supportive conditional logistic
regression analyses.
In the case of time-to-event data, the stratified NPANCOVA analysis could be
used when covariate adjustment is desired but the assumptions of a stratified Cox
proportional hazards model may not hold. Specifically, the appropriate functional form
of the covariates can not be verified a priori, and most importantly, the proportional
hazards assumption can not be shown to hold for the covariates before data is collected.
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The methodology does use a treatment-only Cox model, but when using the Efron
method for handling ties, the p-value from the treatment-only model is similar to that
from the nonparametric stratified logrank test. The NPANCOVA analysis does provide
the additional robustness of not requiring the proportional hazards assumption for the
covariates. Example 3.3.2 reflects this, as further analysis using scaled Schoenfeld
residuals (not shown) appeared to show violation of proportional hazards for one of the
baseline covariates.
The covariance matrix Vf for f presented in Section 3.2.1 is an extension of the
covariance matrix in Koch et. al. (1998) for the stratified setting. It assumes that the
patients are like a random sample from a corresponding stratified population, and it is
formed in a way that is similar to the covariance matrix in Saville and Koch (Saville and
Koch, 2013). Another specification for the covariance matrix of f , V˜f , is developed
using multivariate U-statistics and is presented in Appendix A.1.1. Results of the
analyses in Appendix A.3 indicate that the covariate-adjusted NPANCOVA estimates
and standard errors are similar, despite some differences in the numerical values of the
covariance matrices. In particular, the comparisons of the components of V˜f with Vf
in Appendix A.1.2 suggest more similarity in the two covariance matrices if stratum
sizes are larger (as in the Neurologic Disorder example) than if they are around 10-20
(as in the Osteoarthritis example). However, whether Vf or V˜f should be used may
be irrelevant; the estimates, standard errors, and p-values were very similar, and the
inference for the treatment effect was the same. A third specification, V¯f , contains
components including the model-based variance and the covariance structure for the
weighted difference in means of the covariates Vg¯ which pertains to Vf . The use of
V¯f resulted in estimates and standard errors that were very similar to those obtained
from using Vf or V˜f , and, for the dichotomized neurologic disorder outcome, the use
of V¯f resulted in a standard error that was smaller than when using the other two
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specifications.
The DFBETA residuals obtained for the analyses are part of standard output in
most software packages. The residuals for the examples in this chapter were obtained
from PROC PHREG in SAS. While the main intent of this procedure is for fitting
proportional hazards models for time-to-event data, it was used to fit the conditional
logistic regression models (via the ’ties=discrete’ option in SAS). This approach is
reasonable since the partial likelihood for time-to-event data reduces to the conditional
likelihood for a dichotomous outcome when all events are assumed to occur at the
same time. The DFBETA residuals output by PROC PHREG are the product of
the estimated variance of βˆ and the score residuals for the ith subject, and these
residuals are produced for all observations with complete data for the time-to-event or
dichotomous outcome. The sum of squares of the DFBETA residuals gives a robust
variance estimate of the treatment effect βˆ (Wei, Lin and Weissfeld, 1989). Storer
and Crowley developed DFBETA residuals for conditional likelihoods, and these can
be requested through PROC LOGISTIC in SAS (Storer and Crowley, 1985). These
residuals are based on the one-step method by starting at the MLE βˆ, deleting the
jth individual from the hth stratum, and making the next Newton-Raphson step to
obtain βˆ(hj) (Storer and Crowley, 1985) (Pregibon, 1981). Then, the DFBETA residual
is given as (βˆ− βˆ(hj))/σˆ where σˆ is the estimated standard error of βˆ from the full data
set. Unlike the DFBETA residuals produced from PROC PHREG, the residuals from
PROC LOGISTIC are only produced for observations from informative strata, and the
robustness of the sum of squares of these DFBETA residuals for variance estimation is
less clear.
For dichotomous outcomes, the methods in Chapter 2 are intended for very small
strata, and the methods in this chapter are intended for larger strata of size ≥ 10. For
time-to-event outcomes, the methods here are useful for a reasonably small number
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of strata as would be appropriate in a stratified time-to-event analysis to ensure the
number of events is large enough for each stratum. In the next chapter, the hybrid
methodology of Saville and Koch is extended to the case of more than two randomized
treatment groups for time-to-event outcomes.
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Table 3.3: Strata Sizes and Number of Events for the 722 Patients Enrolled on the
Placebo, 100 mg, or 200 mg Arms of the Neurologic Disorder Trial for Example 3.3.2
Strata Sample Size (%) Number of Events (%)
1 234 (32.3) 113 (34.8)
2 100 (13.9) 69 (21.2)
3 168 (23.3) 52 (16.0)
4 78 (10.8) 42 (12.9)
5 96 (13.3) 29 (8.9)
6 46 (6.4) 20 (6.2)
722 (100.0) 325 (100.0)
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Table 3.5: Strata Sizes for the 218 Patients with Data for Visits 1, 2, and 3 in the
Osteoarthritis Randomized Crossover Trial for Example 3.3.3
Study Site Sample Size (%)
1 7 (3.2)
2 21 (9.6)
3 10 (4.6)
4 30 (13.8)
5 6 (2.8)
6 15 (6.9)
7 3 (1.4)
8 22 (10.1)
9 19 (8.7)
10 45 (20.6)
11 21 (9.6)
12 19 (8.7)
218 (100.0)
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Chapter 4
Covariate-adjusted Log Hazard
Ratios using Cox Proportional
Hazards Regression and
Nonparametric
Randomization-Based ANCOVA for
More Than Two Treatments
4.1 Introduction
Analysis of covariance for time-to-event outcomes may occur through the Cox pro-
portional hazards model (Cox, 1972). This model allows for estimation of a log hazard
ratio (or ratios) for comparing two (or more) treatments while adjusting for covariables.
The main assumption of using the Cox model is that the covariates (including treat-
ment) satisfy proportional hazards. That is, the multiplicative effect of a treatment (or
influence of a covariate) on the underlying hazard function is assumed constant over
time. Another assumption is that the covariates themselves have the correct functional
form. For continuous covariates, this involves understanding of the relationship between
the covariate and the log hazard function. In the regulatory setting, analyses must be
specified in a protocol prior to data collection. Thus, the statistical assumptions of a
Cox model are not verifiable a priori and its use for the primary analysis of a random-
ized clinical trial in this setting may lead to questionable results if the assumptions do
not hold.
The general NPANCOVA strategy has been applied to continuous, dichotomous,
and ordinal outcomes (Koch et al., 1998), (Tangen and Koch, 1999a), (Kawaguchi,
Koch and Wang, 2011). Tangen and Koch (Tangen and Koch, 1999b) applied the
methodology to time-to-event outcomes via differences in mean logrank or Wilcoxon
scores, but this does not provide a log hazard ratio. A subsequent method by Moodie et.
al. (Moodie et al., 2011) provided a log hazard ratio based on the means of indicators for
risk and survival for pre-determined time intervals, but this does not have the optimal
properties of the log hazard ratio provided from the Cox model.
Methods introduced by Saville and Koch (Saville and Koch, 2013) use the estimated
log hazard ratios from a treatment-only Cox proportional hazards model for multivari-
ate time-to-event outcomes as part of covariance adjustment provided through NPAN-
COVA. The compound difference vector contains the unadjusted log hazard ratios from
the treatment-only Cox model as well as the difference in means of the covariables be-
tween the two treatment groups. The covariance matrix for the compound difference
is obtained through three components: (1) A robust estimator for the covariance ma-
trix of the estimated log hazard ratios provided through the DFBETA residuals from
the treatment-only Cox model (Wei, Lin and Weissfeld, 1989), (2) the estimated co-
variance matrix of the difference in means of covariables derived through multivariate
U-statistics, and (3) the covariance matrix of the estimated log hazard ratios and the
difference in means of the covariables. The compound vector and its covariance matrix
are then used in weighted least squares to obtain a covariate-adjusted estimate of the
log hazard ratios.
The NPANCOVA strategies described thus far have been created for randomization
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to two treatment groups. Since many clinical trials have randomization to more than
two groups either because of multiple treatments or multiple doses, there is interest
in adapting the methodology to these settings. This chapter introduces methodology
for extension of the treatment-only Cox proportional hazards model and NPANCOVA
(Saville and Koch, 2013) to more than two treatment groups. Covariate-adjusted log
hazard ratios are estimated for pairwise comparisons of each group with a referent
group. Where the multiple treatment groups correspond to multiple doses of the same
treatment, global assessment of an experimental treatment versus control may proceed
through testing a linear contrast (i.e. trend) for better response with increasing dose.
Subsequent assessment of pairwise differences in treatment groups could then occur
with appropriate management of multiplicity (Tangen and Koch, 2001). An additional
extension is provided for the estimation of treatment effects which have departures
from proportional hazards in the sense of time by treatment interaction for their vari-
ation across pre-determined time intervals. This methodology has utility for providing
covariate-adjusted estimates of log hazard ratios for pairwise comparisons of treatments
and assessing the extent of their homogeneity. The methods are presented in Section
4.2, followed by an example and subsequent discussion.
4.2 Methods
4.2.1 Methodology for More than Two Treatment Groups and
One Time-to-Event Outcome
Let Tj be the failure time (or censoring time if no event) for patient j and zij =
1 if patient j is randomized to treatment group i (i = 1, . . . , s − 1) and zij = 0
otherwise. This construction creates s − 1 indicator variables for treatment groups
i = 1, . . . , s−1 with the sth treatment group being the referent group. The unadjusted
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Cox proportional hazards model for the time-to-event outcome is in (4.1).
λj(t; z1j, . . . , z(s−1)j) = λ0(t)exp(β1z1j + . . .+ βs−1z(s−1)j) (4.1)
Here, λj(t; z1j, . . . , z(s−1)j) is the hazard function for patient j and λ0(t) is the underlying
baseline hazard function for the sth treatment group.
With n =
∑s
i=1 ni individuals, let r
(i) = (r
(i)
1 , . . . , r
(i)
n )′ be the vector of n unstan-
dardized DFBETA residuals from fitting the model in (4.1) for the comparison of the ith
treatment group with the sth treatment group (i = 1, . . . , s−1). The DFBETA residual
r
(i)
j is the approximate change in the log hazard ratio comparing the ith group to the sth
group when the jth individual is omitted. Wei et. al. (1989) showed r(i)
′
r(i) provides a
robust variance estimate of the estimated log hazard ratio comparing the ith group to
the sth group (Wei, Lin and Weissfeld, 1989). With R = (r(1), . . . , r(s−1)) representing
the n × (s − 1) matrix of the DFBETA residuals, the matrix Vβˆ = R′R is a robust
covariance matrix estimate for the estimated log hazard ratios βˆ = (βˆ1, . . . , βˆs−1)′ for
the s− 1 comparisons with the sth group.
Let X i = (xi1, . . . ,xiP ) be the ni × P matrix of P baseline covariates for the ni
individuals from the ith treatment group. With x¯i = (x¯i1, . . . , x¯iP )
′ representing the
vector of covariate means for group i, the covariance matrix Vx¯i = (X i − 1x¯i′)′(X i −
1x¯i
′)/[ni(ni−1)] = A′iAi is the estimated covariance matrix of the covariate means for
group i (with 1 being an ni × 1 vector of ones). Here, Ai = (X i − 1x¯i′)/
√
ni(ni − 1).
Let d = (βˆ
′
, (x¯1 − x¯s)′, . . . , (x¯s−1 − x¯s)′)′ = (βˆ′,u′)′ be the ((P + 1)(s − 1)) × 1
compound vector of estimated log hazard ratios and differences in baseline covariate
means for the s− 1 treatment comparisons. Then Vd in (4.2) is the ((P + 1)(s− 1))×
((P + 1)(s − 1)) covariance matrix of d where Vβˆ = R′R is the estimated covariance
matrix for the estimated log hazard ratios, Vx¯i +Vx¯s is the estimated covariance matrix
for (x¯i− x¯s), Vx¯s is the estimated covariance matrix for (x¯i− x¯s) with (x¯i′− x¯s) where
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i 6= i′, and Vβˆ,x¯i − Vβˆ,x¯s is the estimated covariance matrix of βˆ and (x¯i − x¯s). With
Ri representing the ni × (s− 1) matrix of DFBETA residuals for the ni individuals in
treatment group i, the quantity Vβˆ,x¯i − Vβˆ,x¯s is estimated by R′iAi −R′sAs. Details
are provided in Appendix A.3.3.
Vd =

Vβˆ Vβˆ,x¯1 − Vβˆ,x¯s Vβˆ,x¯2 − Vβˆ,x¯s . . . Vβˆ,x¯s−1 − Vβˆ,x¯s
Vx¯1 + Vx¯s Vx¯s . . . Vx¯s
. . . . . .
...
. . . Vx¯s
Vx¯s−1 + Vx¯s

=
 Vβˆ Vβˆ,u
V ′
βˆ,u
Vu

(4.2)
Weighted least squares is then used to produce covariate-adjusted estimates b of the log
hazard ratios by forcing the difference in means for the covariables to zero on the basis
of this expected structure from randomization. This has invocation for d by fitting
the model Z = [I(s−1) 0(s−1)×P (s−1)]′ to d, where I(s−1) is a (s− 1)× (s− 1) identity
matrix and 0(s−1)×P (s−1) is a (s−1)×P (s−1) matrix of zeroes. The covariate-adjusted
estimator b is given in (4.3).
b = (Z ′Vd−1Z)−1Z ′Vd−1d
= βˆ − Vβˆ,uV −1u u
(4.3)
and a consistent estimator for the covariance matrix of b is Vb in (4.4).
Vb = (Z
′Vd−1Z)−1
= Vβˆ − Vβˆ,uV −1u V ′βˆ,u
(4.4)
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These estimators b have an approximate multivariate normal distribution when the
sample sizes for each treatment group are sufficiently large for d to have an approxi-
mate multivariate normal distribution provided βˆ also has an approximate multivariate
normal distribution. Individual hypothesis tests for the log hazard ratios comparing
each group i with group s can be conducted using the statistic b2i /vb,i where bi is the es-
timated adjusted log hazard ratio and vb,i is the estimated variance of bi. This statistic,
through the approximate normality of bi, has an approximate chi-squared distribution
with one degree of freedom. A 100(1−α)% confidence interval for each log hazard ratio
may be obtained through bi ± z1−α/2√vb,i where z1−α/2 is the (1− α/2)th percentile of
a standard normal distribution. As the differences in means of the covariables between
treatment groups are expected to be zero due to randomization, the extent of random
imbalances between groups for the means of the covariates may be evaluated through
Q0 in (4.5).
Q0 = (d−Zb)′Vd−1(d−Zb) (4.5)
This criterion approximately has the chi-squared distribution with P (s− 1) degrees of
freedom.
In the case of the treatment groups being different doses of an experimental treat-
ment vs. a control, Tangen and Koch (2001) provide guidance on assessment of treat-
ment effects in a manner which appropriately controls the experimentwise significance
level. Global assessment of efficacy for the treatment vs. control can first proceed with
a linear contrast based on prior understanding of the underlying dose-response relation-
ship. For the NPANCOVA setting, this can be achieved by the appropriate specification
for a contrast c. For example, with high, medium, and low dose groups compared to
placebo as a referent group, if the high and medium doses were thought to have similar
effect but perform better than low dose, one could test the average of high and medium
doses versus placebo at significance level α as an initial global assessment through the
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hypothesis H0 : c
′b = 0. Here, c′ = (1 1 0) and b′ = (b1 b2 b3) so that b1 represents the
covariate-adjusted log hazard ratio for high dose vs. placebo, b2 represents medium vs.
placebo, and b3 represents low vs. placebo. This contrast can be tested using the statis-
tic Qt = (cb)
′(cV bc′)−1(cb). Qt then has an approximate chi-squared distribution with
one degree of freedom. Once an overall treatment effect has been established through a
significant p-value for the global assessment, individual pairwise comparisons between
the treatment groups could be conducted. Kong et. al. (2005) offer some strategies for
managing subsequent testing after the global assessment. In the example, if the test of
the average of high and medium doses (versus placebo) is statistically significant, one
could then test both high vs. placebo and medium vs. placebo at the full α. If both
tests are statistically significant, one can then test low vs. placebo, and if significant,
one could proceed to test other comparisons for the treatment groups in a manner like
that in Kong et. al. (2005). For example, one could test the average of high and
medium doses versus low; and if its result was significant, then one could test high
versus low, medium versus low, and high versus medium at the full α on the basis of
closed testing principles (Kong et al., 2005).
Alternatively, one could assess overall homogeneity of the log hazard ratios through
the statistic Qh = (Lb)
′(LV bL′)−1(Lb) where L = Is−1. Qh has an approximate chi-
squared distribution with s − 1 degrees of freedom. Rejection of the null hypothesis
H0 : Lb = 0 would then allow for subsequent assessment of the pairwise treatment
comparisons with appropriate consideration for multiplicity.
4.2.2 Estimation of Log Hazard Ratios for Time-Varying Treat-
ment Effects with More than Two Treatment Groups
In some cases of non-proportional hazards for the treatment variable, a Cox model
may be fit which accommodates the treatment indicators as time-varying covariates.
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When hazard ratios are thought to be different before and after a fixed time t∗, the
time-dependence can be modeled using an indicator variable w(t) where w(t) = 1 if
t > t∗ and w(t) = 0 if t ≤ t∗. The Cox model then takes the form in (4.6).
λj(t; z1j, . . . , z(s−1)j, w(t)) =
λ0(t)exp(β˜1z1j + . . .+ β˜s−1z(s−1)j + γ1w(t)z1j + . . .+ γs−1w(t)z(s−1)j) (4.6)
The vector of log hazard ratios for the s − 1 treatment comparisons for time [0, t∗]
as well the s − 1 comparisons for time t > t∗ can be represented by the vector ˆ˜β =
( ˆ˜β1, . . . ,
ˆ˜βs−1, (
ˆ˜β1 + γˆ1), (
ˆ˜β2 + γˆ2), . . . , (
ˆ˜βs−1 + γˆs−1))′. The vector d˜ can be created as in
Section 4.2.1 where ˆ˜β replaces βˆ.
The covariance matrix Vd˜ can be constructed in a similar manner as in Section
4.2.1, where V ˆ˜β replaces Vβˆ and V ˆ˜β,x¯i
replaces Vβˆ,x¯i . To obtain the 2(s− 1)× 2(s− 1)
covariance matrix V ˆ˜
β
, duplicate records are created in the data set for patients with
Tj > t
∗. Patients with Tj ≤ t∗ have one record in the data set where the failure (or
censoring) time is Tj. For patients with Tj > t
∗, the first record denotes observation
over [0, t∗] with censoring at time t∗ and the second record denotes observation over
(t∗, Tj] with failure (or censoring) at Tj. Let R = (Q1 Q2) be the n× 2(s− 1) matrix
of DFBETA residuals where Q1 is the n × (s − 1) matrix of DFBETA residuals from
a treatment-only Cox proportional hazards model on records relating to [0, t∗] and Q2
is the matrix of DFBETA residuals from a treatment-only Cox proportional hazards
model on records relating to (t∗, Tj] with zeroes replacing missing values in Q2 for
patients with Tj ≤ t∗ so as to create a n × (s − 1) matrix. Then V ˆ˜β = R′R is a
robust covariance estimate of the log hazard ratios ˆ˜β. The 2(s − 1) × P matrices
for the estimated covariances of ˆ˜β and (x¯i − x¯s) with i = 1, . . . , s − 1 are given by
V ˆ˜
β,x¯i
− V ˆ˜
β,x¯s
= R′iAi − R′sAs where Ri is the ni × 2(s − 1) matrix of DFBETA
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residuals for the ni individuals in treatment group i.
Weighted least squares may then be applied using the vector d˜, the covariance
matrix Vd˜, and the model Z˜ = I2(s−1) to obtain the 2(s− 1)× 1 vector b˜ of covariate-
adjusted estimates of the log hazard ratios for treatment comparisons during [0, t∗]
and treatment comparisons in (t∗,maxj Tj]. The log hazard ratios are estimated by
b˜ = (Z˜
′
Vd˜
−1Z˜)−1Z˜
′
Vd˜
−1d˜ and a consistent estimator of the covariance matrix of b˜
is Vb˜ = (Z˜
′
Vd˜
−1Z˜)−1. Individual hypothesis tests for each log hazard ratio may be
conducted through the statistic b˜2im/vb˜,im where b˜im is the estimated log hazard ratio
for the ith treatment comparison in the mth time interval (m = 1, 2), and vb˜,im is its
estimated variance. This statistic has an approximate chi-squared distribution with
one degree of freedom. A 100(1−α)% confidence interval for each log hazard ratio may
be obtained through b˜im± z1−α/2√vb˜,im. As in Section 4.2.1, random imbalances in the
means of the covariables may be assessed with the statistic Q˜0 = (d˜−Z˜b˜)′Vd˜−1(d˜−Z˜b˜)
which has an approximate chi-squared distribution with P (s− 1) degrees of freedom.
4.3 Example
The clinical trial data for management of an incurable neurologic disorder from Ex-
amples 3.3.1 and 3.3.2 were re-examined for this example. For the subsequent analyses,
all 959 patients randomized to one of four treatment groups (placebo, 50 mg, 100 mg,
and 200 mg) were included. The primary treatment comparison for the study was 100
mg vs. placebo. The same six baseline covariates of age, disease duration (years),
weight, and three continuous measures of neurologic and musculoskeletal function as
the analysis in Examples 3.3.1 and 3.3.2 were used. However, the following examples
do not include stratification by geographic region/site of disease onset. The primary
event of interest was time until progression of disease.
72
4.3.1 Comparison of Four Treatment Groups: Neurologic Dis-
order Data
Time to progression of disease is described via Kaplan-Meier curves in Figure 4.1.
The curves appear to overlap for about the first 100 days after randomization be-
fore they begin to separate. The treatment groups then all appear to have better
progression-free survival than the placebo group for the remainder of the observation
time. There are times where the 100 mg group appears to perform better than the
200 mg group, although the two curves do cross over each other a few times past the
100-day mark. The 50 mg and 100 mg curves appear to have clear separation, but the
50 mg and 200 mg curves do eventually cross at about 435 days.
Figure 4.1: Progression-Free Survival for Neurologic Data from Example 4.3.1 with
Four Treatment Groups
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The results for the treatment comparisons with placebo are presented in Table 4.1.
The unadjusted analyses did not show any statistically significant treatment effects (at
the 0.05 level) for any of the treatment groups as compared to placebo. The p-values
for these comparisons were p=0.2545, p=0.0864, and p=0.0950 for the 50 mg, 100 mg,
and 200 mg treatment groups, respectively. After adjustment for baseline covariates
via NPANCOVA, the 50 mg vs. placebo comparison showed a 16.5% reduction in the
standard error as compared to the unadjusted analysis (NPANCOVA S.E.=0.1121 vs.
unadjusted S.E.=0.1342). A 16.7% reduction in standard error due to adjustment via
NPANCOVA was observed for both the 100 mg vs. placebo and the 200 mg vs. placebo
comparisons. Statistical significance at the 0.05 level was attained for these latter two
adjusted comparisons (p=0.0065) and (p=0.0084).
For all three treatment comparisons, the Cox proportional hazards model produced
more significant p-values than NPANCOVA. The p-values for the Cox model were due
to the estimates being further away from the null value of zero and having larger stan-
dard errors than both the NPANCOVA estimates and the unadjusted estimates. The
NPANCOVA hazard ratios were closer to 1.0 than the hazard ratios from the Cox
model since the NPANCOVA estimates are like population-averaged hazard ratios and
the Cox hazard ratios have a conditional interpretation through individuals from dif-
ferent treatment groups who share the same values of the covariates. The assessment
of random imbalances in covariate means between the treatment groups was support-
ive (Q0 = 9.2352, df = 18, p = 0.8649) and indicated a lack of evidence for random
imbalances.
Following the guidance of Tangen and Koch (2001) and Kong et. al. (2005), a
test of H0 : c
′b = 0 for the average of 200 mg and 100 mg doses versus placebo was
conducted using the contrast c′ = (0 1 1) since the ordering of the estimates in b are
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50 mg vs. placebo, 100 mg vs. placebo, and 200 mg vs. placebo. This global assess-
ment had p=0.0970 unadjusted and p=0.0117 adjusted, indicating a treatment effect
over placebo for the covariate-adjusted estimates. Subsequent tests of 200 mg versus
placebo and 100 mg versus placebo (for covariate-adjusted estimates) were statistically
significant with p=0.0065 and 0.0084 as described above. Given that these were both
significant, one could test 50 mg versus placebo (p=0.1229). It is at this point that
testing would stop and one would conclude efficacy of both the 100 mg and 200 mg
doses without formal comparison of these two doses. Alternatively, one could examine
the test for homogeneity which had p=0.2735 unadjusted and p=0.0180 adjusted, in-
dicating covariate-adjusted treatment effects were different for at least one pair of dose
groups.
4.3.2 Comparison of Four Treatment Groups with Time-Varying
Treatment Effects
The data from the previous analysis was considered with the inclusion of time-
varying treatment effects. The treatment effect might possibly delay progression of the
neurologic disorder for a period of time but not postpone it indefinitely. Thus, separate
hazard ratios were of interest for an earlier period (0-12 months) and a later period
(12-18 months). The implementation of the methodology in Section 4.2.2 involved the
creation of an indicator variable w(t) where w(t) = 1 if t > 365.25 (days) and w(t) = 0
if t ≤ 365.25 (days).
Estimates of the parameters (γ1, γ2, γ3) for the three interaction terms are presented
in Table 4.2. The Cox model analysis with adjustment for the six baseline covariates
did not show evidence of interaction for any of the treatment comparisons (p>0.20 for
all comparisons). For the unadjusted analysis, there was weak evidence of differences
in the log hazard ratios for 0-12 months and 12-18 months for the 50 mg vs. placebo
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(p=0.1781) and the 200 mg vs. placebo (p=0.1285) comparisons. However, the 100
mg vs. placebo comparison (p=0.0485) suggested the presence of interaction. After
adjustment for covariates, the NPANCOVA analysis corroborated the results of the
unadjusted analysis with p=0.1533, p=0.0531, and p=0.1406 for the 50 mg vs. placebo,
100 mg vs. placebo, and 200 mg vs. placebo comparisons, respectively.
The estimated log hazard ratios for the three treatment comparisons for 0-12 months
and 12-18 months are presented in Table 4.3. For the 0-12 month 50 mg vs. placebo,
12-18 month 100 mg vs. placebo, and 12-18 month 200 mg vs. placebo comparisons,
the NPANCOVA analysis produced covariate-adjusted estimates that were between the
unadjusted estimates and the Cox adjusted estimates. For the other comparisons, the
NPANCOVA analysis produced covariate-adjusted estimates that were slightly larger
than the unadjusted estimates. However, the hazard ratio estimates for the NPAN-
COVA analysis were similar to those from the unadjusted estimates, reflecting the
unconditional nature of the NPANCOVA estimates. This is in contrast to the esti-
mated hazard ratios from the Cox model which were further away from the null value
of 1.0 and which have a conditional interpretation on the basis of individuals with the
same values for the baseline covariates.
For the 0-12 month time period, there were small reductions in the standard error
after covariate adjustment via NPANCOVA (vs. unadjusted) for all three treatment
comparisons. Both the unadjusted and NPANCOVA analyses suggest a significant ef-
fect (at the 0.05 level) of the 100 mg dose over placebo (p=0.0128 and p=0.0157) as
well as the 200 mg dose over placebo (p=0.0257 and p=0.0251), but there was not
enough evidence to conclude the 50 mg dose was efficacious (p=0.0918 and p=0.0804).
For this time period, the effect of the 100 mg dose was observed to be slightly stronger
than the effect of the 200 mg dose, yet the two groups had similar effects. Although the
standard errors for the estimates from the Cox model were larger than the NPANCOVA
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analyses (with the exception of the 50 mg vs. placebo comparison, the estimates them-
selves were also of greater magnitude and produced significant p-values for all three
treatment comparisons.
For the 12-18 month time period, small reductions in the standard errors were
again observed for NPANCOVA as compared to the unadjusted analysis, but none
of the estimated treatment effects were statistically significant. The unadjusted and
NPANCOVA analyses produced estimated hazard ratios which favored placebo over
the treatment, but the Cox model estimates continued to produce estimated hazard
ratios less than 1.0, indicating the possible influence of Simpson’s paradox (Simpson,
1951).
4.4 Discussion
This chapter presents nonparametric methodology for obtaining covariate-adjusted
estimates of log hazard ratios when individuals are randomized to one of several treat-
ment groups. These methods expand upon work by Saville and Koch for two random-
ized groups as an alternative to the Cox proportional hazards model (Saville and Koch,
2013). The NPANCOVA methods force the differences in means of covariables between
treatment groups to zero as is expected under a valid randomization, thereby obtaining
the covariate-adjusted treatment effects. The main assumptions for the NPANCOVA
method are a valid randomization, adequate sample size to invoke approximate nor-
mality of the estimated log hazard ratios, and the proportional hazards assumption on
the treatment variables. However, this latter assumption may be avoided by estimating
separate covariate-adjusted log hazard ratios in time intervals where the hazard ratios
are assumed constant.
The NPANCOVA methods do not require the assumption of proportional hazards
for the covariates, and thus they are an attractive alternative to Cox proportional
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hazards models in a regulatory setting where the proportional hazards assumption on
the covariates can not be verified during the planning stages of a clinical trial. For the
example, one of the six baseline covariates showed violation of the proportional hazards
assumption, causing possible concern about the Cox model estimates. Additionally,
the methods presented here generally produce smaller standard errors of the log hazard
ratios as compared to the unadjusted analyses. This is manifested in smaller p-values
and thus more powerful tests.
Since the methods in this chapter require the specification of a referent treatment
group, the pairwise comparisons between each treatment group and the referent group
are correlated. Instead of considering separate NPANCOVA analyses for each treatment
comparison, the methods presented here account for this correlation. The methodology
can also accommodate contrasts of the adjusted log hazard ratio estimates. For the ex-
ample, such contrasts could produce the log hazard ratios for the pairwise comparisons
between the 50 mg, 100 mg, and 200 mg treatment groups after a global assessment of
efficacy through a test of linear trend.
There are limitations associated with the NPANCOVA methods presented here. The
covariate adjustment via weighted least squares requires complete covariate data. In
the event of missing covariate data, an appropriate multiple imputation strategy would
be warranted so as not to potentially bias treatment effects via removal of patients
with missing data from the analysis. Removing patients may affect the distribution of
covariables and thus the expected differences in means of the covariables between treat-
ment groups may no longer be zero. Additionally, the NPANCOVA methods produce
population-averaged estimates of treatment effects and hence can not produce estimated
log hazard ratios in subgroups defined by the covariates. Additionally, interactions be-
tween treatment variables and covariates can not be accommodated. The interaction
of the treatment variable with continuous time in a Cox model is a convenient way to
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accommodate a time-varying treatment effect. However, time-varying treatment effects
in NPANCOVA may only be handled through the estimation of separate hazard ratios
for pre-determined time intervals.
The NPANCOVA methods here are appropriate in a regulatory environment to
provide covariate-adjusted estimates of treatment effects for the primary analysis in
a clinical trial. The methods avoid the proportional hazards assumption on the co-
variates, and thus the authors recommend the use of the NPANCOVA methods for
the primary analysis followed by supportive secondary analyses using the Cox model.
These secondary analyses could explore subgroup differences in treatment effects, and
the effects of model assumptions on the results could be assessed through comparison
with the NPANCOVA results.
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Chapter 5
Summary and Future Research
5.1 Summary
The methods in the previous chapters describe several extensions of nonparamet-
ric randomization-based analysis of covariance. Chapter 2 provides methodology for
covariance adjustment in the analysis of dichotomous outcomes for 1:1 matched sets,
M : 1 matched sets, and the 1:1 non-randomized matched case control study. These
techniques are an alternative to either the unadjusted McNemar’s test or conditional lo-
gistic regression. The NPANCOVA methods avoid the assumptions of functional form
of the covariates, and they only require a valid randomization (for exact inference).
Confidence intervals for the covariate-adjusted difference in proportions (or odds ratio)
may be obtained if the study participants can be assumed to be like a simple ran-
dom sample from a corresponding population. For the examples presented, a decrease
in standard errors for the treatment effect estimates was observed, resulting in more
precise estimates.
Chapter 3 extends the methodology of Saville and Koch (2012) to the analysis of
dichotomous and time-to-event outcomes in the presence of stratification. DFBETA
residuals from a treatment-only conditional logistic regression (or stratified Cox pro-
portional hazards model, for the time-to-event outcome) are used to create a robust
estimate of the covariance matrix for the model-based log odds ratio (or log hazard ra-
tio). This information is combined with covariate information to produce a covariance
matrix which can be used for the nonparametric covariance adjustment via weighted
least squares. The nonparametric covariance adjustment produces standard errors for
the estimated treatment effect that are smaller in comparison to the standard errors
from a stratified analysis with no other covariates besides treatment.
The methods of Saville and Koch are also extended to the setting of multiple ran-
domized treatment groups for time-to-event outcomes. The techniques presented begin
with a treatment-only Cox proportional hazards model and use the DFBETA resid-
uals from this model to obtain a robust covariance matrix for the log hazard ratios.
The DFBETA residuals are then combined with the covariate information to obtain
a covariance matrix which can be used in the nonparametric covariance adjustment.
The difference vector in this setting uses pairwise differences between each treatment
group and a referent group, although contrasts for the covariate-adjusted log hazard
ratios may be used to assess trends corresponding to increasing dose. Tangen and Koch
(2001) provide guidance on how these hypothesis tests can be conducted.
5.2 Considerations and Limitations
5.2.1 Missing Data
For all of the methods above, there is an assumption that none of the outcome data
or covariate data is missing. The methods do not have a capability to handle missing
data directly. In the presence of missing data in a randomized trial, analyzing only
complete cases might result in the two randomized groups not being strictly comparable
on the basis of the covariables. Thus, it is recommended that the missing covariate
data be imputed by some appropriate multiple imputation method before applying
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NPANCOVA. For missing outcome variables, the missing data mechanism (e.g. MCAR,
MAR, or NMAR) should be posited, and then appropriate methods considered for
handling the missingness. The NPANCOVA methods are appropriate for analysis of
the primary endpoint of a study, and NPANCOVA could be applied to imputed data
sets in a sensitivity analysis to assess the influence of the missing data.
5.2.2 Limitations
The nonparametric covariance adjustment described for these methods is done via
weighted least squares using a model which forces the differences in means of the co-
variables between the randomized groups to zero. As a result, relationships between
the covariables and the outcome can not be estimated. Thus, for the regulatory set-
ting, the NPANCOVA methods are intended for analysis of the primary endpoint in
a clincal trial. Once efficacy is established through NPANCOVA, secondary analyses
may be conducted using parametric models. These models may include assessment of
treatment effects for certain subgroups or interactions between treatment effects and
levels of the other covariates.
5.3 Future Research
The methods for matched sets presented in Chapter 2 are appropriate in the case of
balanced allocation. Example 2.3.2 does involve the use of weighting estimates across
type of matched sets, although the sample sizes within the matched sets are the same
in this case. A further direction of research for this methodology may involve the
extension to situations of unbalanced allocation when the matched sets have variable
size. The extension of the NPANCOVA methodology to randomized studies with M :N
matching (where M and N are both ≥ 2 but ≤ 4) is straightforward. The difference
in mean responses would be formed for the two treatment groups for each matched
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set, and formation of f¯ and Vf¯ would proceed as previously outlined. For the odds
ratio, the methodology presented in Section 2.2.3 could be extended via a Mantel-
Haenszel estimate of the odds ratio or a conditional maximum likelihood estimate as in
(Miettinen, 1970), but this is beyond the scope of this research. In practice, M and N
are rarely greater than 3, and so the methodology here is most applicable for matched
pairs and matched sets of size ≤ 6. For larger matched sets, the methodology presented
in Chapter 3 may be more appropriate.
For the NPANCOVA methodology as applied to matched sets in Chapter 2, several
extensions of the NPANCOVA methdology are possible. While only dichotomous out-
comes are considered, these methods may be easily extended to continuous outcomes
through a covariate-adjusted difference in means. Repeated outcome measures through
multiple assessments (e.g. clinic visits) could be managed by including entries in the
difference vector for each pair corresponding to the differences that the respective as-
sessments have for the responses for the two treatments. In the case of 1:1:1 randomized
allocation to treatments A,B, or C (matched triples), the difference vector for stratum
h could contain the A-C difference in response, the B-C difference in response, and
such differences for the covariates for adjustment. Formation of the appropriate mean
vector and its covariance matrix would follow per Section 2.2.1. Subsequent assessment
of ordinality of the treatment effects could be accomplished via hypothesis testing of
contrasts for the vector of covariate-adjusted estimates.
The methods in Chapter 3 and 4 could be combined in the case of a randomized
study with stratification and multiple treatment groups. Extension to ordinal outcomes
and counts is a possibility, although it has not yet been determined whether the cross-
products of the DFBETA residuals from a treatment-only proportional odds model or
Poisson regression model can be used to obtain a valid robust estimate of the covariance
matrix for the log odds ratios or log rate ratios. In the case of repeated measures, there
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is the possible extension of the Saville and Koch methodology using the DFBETA
residuals from generalized estimating equations (GEE). Preisser and Qaqish (1996) have
developed cluster-level DFBETA residuals (i.e. DFBETA residuals based on deleting
an entire cluster’s observations) and observation-level DFBETA residuals (i.e. based on
deleting one observation within a cluster) which are available in standard software, and
the cross-products of the cluster-level DFBETA residuals have been shown to exactly
equal a bias-corrected covariance estimator in the GEE setting (Mancl and Derouen,
2001). Accommodating baseline covariates in this setting is straightforward, and it
would be possible to use two or more of the repeated measures (e.g. a pre-baseline
measure and its baseline counterpart) as covariates. However, it is currently unclear how
to easily manage adjustment of similar measures on different scales (e.g. a dichotomized
baseline value included as an outcome measure and its continuous counterpart included
as a baseline covariate).
While the research presented here offers a theoretical road map for the NPANCOVA
methods in these settings, a future direction of the research could be to assess the per-
formance of the NPANCOVA methods in this paper as they relate to the parametric
modeling methods. Simulations would be a necessary next step to ensure that the
NPANCOVA methods do not result in any Type I error increase beyond the nomi-
nal level as well as to ensure that the methods have adequate power for testing the
hypotheses of interest. From the examples presented here, one can observe that the
power to test coefficients relating to the treatment effects is greater when there is co-
variance adjustment than when there is no covariance adjustment (when the standard
errors show a decrease after adjustment). However, regarding power, it is unclear how
the NPANCOVA methods perform compared to the parametric ANCOVA methods.
Jiang et. al. have conducted a simulation study comparing the NPANCOVA methods
of Tangen and Koch (1999) for logrank and Wilcoxon scores to the Cox proportional
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hazards model. They showed that the NPANCOVA methods did preserve the nominal
Type I error and that there was a small loss in efficiency of the NPANCOVA methods
when the proportional hazards assumption was correct (Jiang et al., 2008). However, in
planning a study, the cost of having a greater sample size for NPANCOVA may be out-
weighed by the benefit of having minimal statistical assumptions when pre-specifying
the primary analysis method. Accordingly, the sample size needed for NPANCOVA
may end up being less than what would be necessary in a nonparametric analysis that
did not adjust for covariables (e.g. logrank test).
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Appendix A: Chapter 3
A.1 Specification of Covariance Matrix V˜f for Compound Vec-
tor in Stratified Analysis using Multivariate U-statistics
A.1.1 Theoretical Specification
Methods for multivariate U-statistics ((Davis and Quade, 1968),(Davis and Quade,
1978),(Kawaguchi, Koch and Wang, 2011)) are used to construct consistent estimates
(different from that in (3.3)) for the covariances of the log odds ratio βˆ and the stratified
difference in means of the covariates (x¯1 − x¯2) as well as for the covariance matrix of
(x¯1− x¯2). Let gjj′ = 0.5 ∗ [I(Sj − Sj′ = 0)(tj − tj′)(xj −xj′)]n(n− 1)/(2W (nj + nj′)),
where nj = nhi if patient j is from group i in stratum h (with nhi being the sample
size for group i in stratum h), Sj denotes the stratum for patient j, tj = 1 if patient
j is from group 1 and tj = −1 if patient j is from group 2, and xj is the vector of
covariates for patient j. Also, I(Sj − Sj′ = 0) = 1 if Sj = Sj′ and it equals 0 if
Sj 6= Sj′ ; Additionally, let W =
∑q
h=1[nh1nh2/(nh)] where q is the number of strata
with nh = nh1 + nh2; also let n =
∑q
h=1
∑2
i=1 nhi. Let gj∗ be the mean of the gjj′
for patient j with averaging across all j′ 6= j, so that the mean g¯ of the gj∗ across
all patients equals the weighted difference in baseline covariate means between the two
groups for the respective strata (with weights (nh1nh2/nh)) with this being denoted as
the stratified difference g¯ = (x¯1 − x¯2).
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gj∗ =
n∑
j 6=j′
gjj′/(n− 1) =

nnh2(xj−x¯h2)
2W (nh1+nh2)
if j from h, group 1
−nnh1(xj−x¯h1)
2W (nh1+nh2)
if j from h, group 2
g¯ =
n∑
j=1
gj∗/n =
[
q∑
h=1
nh1nh2(x¯h1 − x¯h2)
(nh1 + nh2)
]
/W = x¯1 − x¯2 (1)
The quantity (gj∗ − g¯) as given is a measure of the deviation of gj∗ about its mean:
(gj∗ − g¯) =

nnh2(xj−x¯h2)
2W (nh1+nh2)
− (x¯1 − x¯2) if j from h, group 1
−nnh1(xj−x¯h1)
2W (nh1+nh2)
− (x¯1 − x¯2) if j from h, group 2
V˜g¯ in (2) is a consistent estimate for the covariance matrix of g¯ ((Davis and Quade,
1968),(Davis and Quade, 1978),(Kawaguchi, Koch and Wang, 2011)).
V˜g¯ =
4
n(n− 1)
n∑
j=1
(gj∗ − g¯)(gj∗ − g¯)′ =
n∑
j=1
g˜jg˜
′
j (2)
The quantity g˜j in (2) is defined as
g˜j =
2√
n(n− 1)(gj∗ − g¯)
=

√
n
n−1
[
nh2(xj−x¯h2)
W (nh1+nh2)
]
− 2(x¯1−x¯2)√
n(n−1) if j from h, group 1
−√ n
n−1
[
nh1(xj−x¯h1)
W (nh1+nh2)
]
− 2(x¯1−x¯2)√
n(n−1) if j from h, group 2
=

√
n
n−1
[
nh2(xj−x¯h1)
W (nh1+nh2)
]
+
√
n
n−1
[
nh2(x¯h1−x¯h2)
W (nh1+nh2)
]
− 2(x¯1−x¯2)√
n(n−1) if j from h, group 1√
n
n−1
[
−nh1(xj−x¯h2)
W (nh1+nh2)
]
+
√
n
n−1
[
nh1(x¯h1−x¯h2)
W (nh1+nh2)
]
− 2(x¯1−x¯2)√
n(n−1) if j from h, group 2
Let f˜ j = (rj, g˜
′
j)
′ and f = (βˆ, (x¯1 − x¯2)′)′, where rj is the DFBETA residual for the
jth patient. Then the covariance matrix of f is estimated by (3), for which the lower
right quantity
∑n
j=1 g˜jg˜
′
j estimates the covariance matrix of the weighted differences
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g¯ = (x¯1− x¯2) in means of covariates, and the upper right quantity
∑n
j=1 rjg˜
′
j estimates
the covariances of the estimated treatment effect βˆ and the weighted differences in
means of covariates.
V˜f =
∑
j
f˜ jf˜
′
j
=
 ∑nj=1 r2j ∑nj=1 rjg˜′j∑n
j=1 g˜jrj
∑n
j=1 g˜jg˜
′
j

=
 vβˆ V˜ ′βˆ,g¯
V˜ βˆ,g¯ V˜g¯

(3)
The quantities in V˜f are estimated by
n∑
j=1
g˜jg˜
′
j =
q∑
h=1
2∑
i=1
nhi∑
k=1
n(nhi − 1)
(n− 1)nhi
[
nh1nh2
nhW
]2 [
(xhik − x¯hi)(xhik − x¯hi)′
nhi(nhi − 1)
]
+
q∑
h=1
n
n− 1
nh1nh2
nhW 2
(x¯h1 − x¯h2)(x¯h1 − x¯h2)′
− 4
n− 1(x¯1 − x¯2)(x¯1 − x¯2)
′
n∑
j=1
rjg˜
′
j =
√
n
n− 1
q∑
h=1
(
1
Wnh
)[
nh2
nh1∑
k=1
rh1k(xh1k − x¯h1)− nh1
nh2∑
k=1
rh2k(xh2k − x¯h2)
]
+
√
n
n− 1
q∑
h=1
(
nh1nh2
Wnh
)
(x¯h1 − x¯h2)(r¯h1 + r¯h2)
− 2√
n(n− 1)(x¯1 − x¯2)
q∑
h=1
(nh1r¯h1 + nh2r¯h2)
Suppose the case of proportional allocation within strata so that nh1 = pnh and nh2 =
(1 − p)nh for 0 < p < 1. Then (nh1nh2/nh) = p(1 − p)nh and W = p(1 − p)n so that
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(nh1nh2)/(nhW ) = (nh)/n. Then,
n∑
j=1
g˜jg˜
′
j =
n
n− 1
q∑
h=1
[∑nh1
k=1(xh1k − x¯h1)(xh1k − x¯h1)′
n2p2
+
∑nh2
k=1(xh2k − x¯h2)(xh2k − x¯h2)′
n2(1− p)2
]
+
1
(n− 1)p(1− p)
q∑
h=1
(nh
n
)
(x¯h1 − x¯h2)(x¯h1 − x¯h2)′
− 4
n− 1(x¯1 − x¯2)(x¯1 − x¯2)
′
and
n∑
j=1
rjg˜
′
j =
√
n
n− 1
q∑
h=1
[
nh1∑
k=1
1
np
rh1k(xh1k − x¯h1)−
nh2∑
k=1
1
n(1− p)rh2k(xh2k − x¯h2)
]
+
√
n
n− 1
q∑
h=1
(nh
n
)
(x¯h1 − x¯h2)(r¯h1 + r¯h2)
− 2
√
n
n− 1(x¯1 − x¯2)
q∑
h=1
(pr¯h1 + (1− p)r¯h2)
(nh
n
)
Furthermore, when stratum sizes are equal so that nh = N for all h, n = Nq, and
(nh/n) = 1/q,
n∑
j=1
g˜jg˜
′
j =
Nq
Nq − 1
q∑
h=1
[∑Np
k=1(xh1k − x¯h1)(xh1k − x¯h1)′
N2q2p2
+
∑N(1−p)
k=1 (xh2k − x¯h2)(xh2k − x¯h2)′
N2q2(1− p)2
]
+
1
(Nq − 1)qp(1− p)
q∑
h=1
(x¯h1 − x¯h2)(x¯h1 − x¯h2)′
− 4
Nq − 1(x¯1 − x¯2)(x¯1 − x¯2)
′
92
n∑
j=1
rjg˜
′
j =
√
Nq
Nq − 1
q∑
h=1
 Np∑
k=1
1
Npq
rh1k(xh1k − x¯h1)−
N(1−p)∑
k=1
1
N(1− p)q rh2k(xh2k − x¯h2)

+
√
Nq
Nq − 1
q∑
h=1
(
1
q
)
(x¯h1 − x¯h2)(r¯h1 + r¯h2)
− 2
√
Nq
Nq − 1
(
1
q
)
(x¯1 − x¯2)
q∑
h=1
(pr¯h1 + (1− p)r¯h2)
In the special case of equal stratum sizes and equal allocation within strata so that
p = 0.5,
n∑
j=1
g˜jg˜
′
j =
q∑
h=1
4Nq
N2q2(Nq − 1)
 2∑
i=1
N/2∑
k=1
(xhik − x¯hi)(xhik − x¯hi)′

+
4
q(Nq − 1)
q∑
h=1
(x¯h1 − x¯h2)(x¯h1 − x¯h2)′
− 4
Nq − 1(x¯1 − x¯2)(x¯1 − x¯2)
′
n∑
j=1
rjg˜
′
j =
√
Nq
Nq − 1
(
2
Nq
) q∑
h=1
N/2∑
k=1
rh1k(xh1k − x¯h1)−
N/2∑
k=1
rh2k(xh2k − x¯h2)

+
√
Nq
Nq − 1
(
1
q
) q∑
h=1
(x¯h1 − x¯h2)(r¯h1 + r¯h2)
−
√
Nq
Nq − 1(x¯1 − x¯2)
q∑
h=1
r¯h1 + r¯h2
q
A.1.2 Numerical Assessment
In this section, numerical comparisons are made between the covariance matrix
presented in Chapter 3, Vf , and the covariance matrix presented in Appendix A.1.1,
V˜f . Specifically, the components of V˜f are presented for comparison. The time-to-
event outcome for the neurologic disorder data (Example 3.3.2) and the dichotomous
outcome for the osteoarthritis data (Example 3.3.3) are used as examples.
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Time-to-Event Outcome: Neurologic Disorder Data
Per the methodology presented in Appendix A.1.1, the submatrix V˜g¯ of the covari-
ance matrix V˜f can be written as the sum of three terms V˜
(1)
g¯ , V˜
(2)
g¯ , and V˜
(3)
g¯ such
that V˜g¯ =
∑n
j=1 g˜jg˜
′
j = V˜
(1)
g¯ + V˜
(2)
g¯ + V˜
(3)
g¯ . Here,
V˜
(1)
g¯ =
q∑
h=1
2∑
i=1
nhi∑
k=1
n(nhi − 1)
(n− 1)nhi
[
nh1nh2
nhW
]2 [
(xhik − x¯hi)(xhik − x¯hi)′
nhi(nhi − 1)
]
V˜
(2)
g¯ =
q∑
h=1
n
n− 1
nh1nh2
nhW 2
(x¯h1 − x¯h2)(x¯h1 − x¯h2)′
V˜
(3)
g¯ = −
4
n− 1(x¯1 − x¯2)(x¯1 − x¯2)
′
Similarly, the submatrix V˜ ′βˆ,g¯ of the covariance matrix V˜f can be written as the
sum of the three terms V˜
(1)
βˆ,g¯, V˜
(2)
βˆ,g¯, and V˜
(3)
βˆ,g¯ such that V˜
′
βˆ,g¯ =
∑n
j=1 rjg˜
′
j = V˜
(1)
βˆ,g¯ +
V˜
(2)
βˆ,g¯ + V˜
(3)
βˆ,g¯. Here,
V˜
(1)
βˆ,g¯ =
√
n
n− 1
q∑
h=1
(
1
Wnh
)[
nh2
nh1∑
k=1
rh1k(xh1k − x¯h1)− nh1
nh2∑
k=1
rh2k(xh2k − x¯h2)
]
V˜
(2)
βˆ,g¯ =
√
n
n− 1
q∑
h=1
(
nh1nh2
Wnh
)
(x¯h1 − x¯h2)(r¯h1 + r¯h2)
V˜
(3)
βˆ,g¯ = −
2√
n(n− 1)(x¯1 − x¯2)
q∑
h=1
(nh1r¯h1 + nh2r¯h2)
The numerical values of the above components for the neurologic disorder data are
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as follows:
V˜
(1)
g¯ =

0.735674 0.007816 0.007736 −0.078093 −0.128323 0.201556
1.898633 −0.018097 0.503850 −0.028688 −0.359576
0.010596 −0.023594 −0.002767 0.027834
1.296853 0.136271 −0.503879
0.900875 −0.040340
4.288783

V˜
(2)
g¯ =

0.025742 0.093216 −0.000738 0.011776 −0.006746 0.005865
0.007758 −0.000300 0.003214 −0.006661 0.009726
0.000135 −0.000363 0.000269 −0.001688
0.017547 −0.003343 0.014425
0.014374 0.007653
0.125534

V˜
(3)
g¯ =

−0.004653 −0.004250 0.000487 −0.004351 0.003133 −0.016605
−0.003882 0.000446 −0.003974 0.002862 −0.015166
−0.000051 0.000455 −0.000328 0.001737
−0.004069 0.002930 −0.015523
−0.002110 0.011180
−0.059256

By comparison, the submatrix Vg¯ of the matrix Vf is as follows:
Vg¯ =

0.749256 0.006666 0.007869 −0.080288 −0.130553 0.205403
1.936482 −0.018418 0.513867 −0.031020 −0.369599
0.010773 −0.023863 −0.002839 0.028431
1.318745 0.139828 −0.515907
0.918900 −0.043385
4.374648

For this example, the entries of the matrix Vg¯ closely resemble the entries of V˜
(1)
g¯ ,
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indicating that the first term V˜
(1)
g¯ tends to dominate the overall sum V˜g¯. The similarity
of the two submatrices is also apparent in Section A.3.2.
The numerical components for the covariance matrix V˜ ′βˆ,g¯ are as follows:
V˜
(1)
βˆ,g¯ =
[
0.032499 −0.049918 −0.001591 −0.042805 −0.014231 0.050800
]
V˜
(2)
βˆ,g¯ =
[
0.000276 0.000157 −0.000046 −0.000228 −0.000792 −0.001831
]
V˜
(3)
βˆ,g¯ =
[
0.000037 0.000033 −0.000004 0.000034 −0.000025 0.000130
]
By comparison, the submatrix V ′βˆ,g¯ is as follows:
V ′βˆ,g¯ =
[
0.032845 −0.050516 −0.001601 −0.043207 −0.014319 0.051279
]
For this example, the entries of the matrix V ′βˆ,g¯ closely resemble those of V˜
(1)
βˆ,g¯,
indicating that the term V˜
(1)
βˆ,g¯ dominates the sum V˜
′
βˆ,g¯. It should be noted that for
this example, there are only six strata and each stratum has fairly large sample size
(median size 123) with a reasonable number of events (median number 47) occurring
in each stratum.
Dichotomous Outcome: Osteoarthritis Data
For the osteoarthritis data example, there are ten strata with stratum sizes ranging
from 10 to 45, with the median stratum size being 20. The components of the covariance
matrix V˜g¯ for the WOMAC outcome is as follows:
V˜
(1)
g¯ =

1.692709 0.006789 −0.123731 −0.326015
0.003603 −0.027473 −0.031371
7.480140 6.810067
8.224089

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V˜
(2)
g¯ =

0.467938 0.006264 0.165081 0.016008
0.000302 −0.000680 −0.001259
1.053048 0.563206
0.507290

V˜
(3)
g¯ =

−0.000966 −0.000096 0.012761 0.012455
−0.000010 0.001271 0.001241
−0.168609 −0.164569
−0.160625

By comparison, the submatrix Vg¯ of the matrix Vf is as follows:
Vg¯ =

1.850647 0.007463 −0.135803 −0.358609
0.003937 −0.029361 −0.033521
8.194083 7.445572
9.009170

There is some similarity in the covariance matrices Vg¯ and V˜
(1)
g¯ , but there is also a
substantial contribution of some of the entries of V˜
(2)
g¯ and V˜
(3)
g¯ to the overall sum V˜g¯.
The numerical components for the covariance matrix V˜ ′βˆ,g¯ for the WOMAC out-
come are as follows:
V˜
(1)
βˆ,g¯ =
[
−0.016282 0.002560 −0.396712 −0.448009
]
V˜
(2)
βˆ,g¯ =
[
−0.008304 −0.000415 0.001101 0.001832
]
V˜
(3)
βˆ,g¯ =
[
0.001090 0.000109 −0.014005 −0.014055
]
By comparison, the submatrix V ′βˆ,g¯ is as follows:
V ′βˆ,g¯ =
[
−0.016620 0.002636 −0.414590 −0.468217
]
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Here, it appears as though the matrices V ′βˆ,g¯ and V˜
(1)
βˆ,g¯ are similar, indicating that
the sum V˜ ′βˆ,g¯ tends to be dominated by the first component V˜
(1)
βˆ,g¯.
A.2 Specification of Covariance Matrix V¯f for Compound Vec-
tor in Stratified Analysis through Transformation
Let Vg¯ and V˜g¯ be the lower right P × P covariance matrices for g¯ = (x¯1 − x¯2) per
the specifications in Chapter 3 and Appendix Section A.1.1, respectively. Also let vβˆ be
the estimated variance of βˆ as the cross-products of the DFBETA residuals, and let vˆβ
be the model-based variance estimate of βˆ from the treatment-only stratified analysis.
The matrices Vg¯ and V˜g¯ can be written as Vg¯ = TT
′ and V˜g¯ = T˜ T˜ ′ where T and T˜
are triangular matrices.
Let D be defined as in (4) where 0 is a P × 1 matrix of zeroes.
D =

√
vˆβ/vβˆ 0
′
0 T T˜
−1
 (4)
Then the matrix V¯f = DV˜fD
′ provides another specification of a covariance matrix
for f which transforms the matrix V˜f so that V¯f has the quantity vˆβ as the [1,1] entry
and Vg¯ as the lower right P × P submatrix.
A.3 Numerical Examples for Different Covariance Specifica-
tions
The analyses conducted in Chapter 3 are revisited using the other specifications of
the covariance matrix for f presented in Appendix A.1.1 and Appendix A.2.
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A.3.1 Dichotomous Outcome: Neurologic Disorder Data
Three specifications of the covariance matrix for f were used to produce the dichoto-
mous outcome analysis results in Table A.3.1 for the 722 patients previously described
in Chapter 3. The first estimate, Vf , is in (5) and was created through the methodology
in Chapter 3.
Vf =

0.029757 0.039911 −0.074802 −0.002201 −0.058199 −0.025258 0.069838
0.749256 0.006666 0.007869 −0.080288 −0.130553 0.205403
1.936482 −0.018418 0.513867 −0.031020 −0.369599
0.010773 −0.023863 −0.002839 0.028431
1.318745 0.139828 −0.515907
0.918900 −0.043385
4.374648

(5)
The second estimate, V˜f , is in (6) and was created through the methodology in
Appendix A.1.1.
V˜f =

0.029757 0.040300 −0.073789 −0.002298 −0.058482 −0.025186 0.068513
0.756763 0.012887 0.007485 −0.070668 −0.131936 0.190815
1.902509 −0.017952 0.503090 −0.032487 −0.365015
0.010680 −0.023503 −0.002825 0.027884
1.310239 0.135858 −0.504981
0.913140 −0.021506
4.355061

(6)
The third estimate, V¯f , is in (7) and was created through the methodology in
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Appendix A.2.
V¯f =

0.029030 0.039607 −0.073863 −0.002251 −0.058562 −0.025006 0.068971
0.749256 0.006666 0.007869 −0.080288 −0.021773 0.205403
1.936482 −0.018418 0.513867 0.205904 −0.369599
0.010773 −0.023863 −0.009212 0.028431
1.318745 0.097392 −0.515907
0.918900 −0.043385
4.374648

(7)
All three of the covariance matrix specifications for NPANCOVA produced similar
odds ratio estimates, standard errors (with V¯f producing the smallest standard error),
and all had a p-value of 0.0002. It should be noted that the standard error using V¯f ,
while not substantially different from the standard error when using Vf or V˜f , did show
a small decrease relative to these other covariance matrix specifications.
A.3.2 Time-to-Event Outcome: Neurologic Disorder Data
Three specifications of the covariance matrix for f were used to produce the time-
to-event analysis results in Table A.3.2 for the 722 patients previously described in
Chapter 3. The first estimate, Vf , is in (8) and was created through the methodology
in Chapter 3.
Vf =

0.013257 0.032845 −0.050516 −0.001601 −0.043207 −0.014319 0.051279
0.749256 0.006666 0.007869 −0.080288 −0.130553 0.205403
1.936482 −0.018418 0.513867 −0.031020 −0.369599
0.010773 −0.023863 −0.002839 0.028431
1.318745 0.139828 −0.515907
0.918900 −0.043385
4.374648

(8)
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The second estimate, V˜f , is in (9) and was created through the methodology in Ap-
pendix A.1.1.
V˜f =

0.013257 0.032776 −0.049761 −0.001636 −0.043033 −0.015023 0.048968
0.756763 0.012887 0.007485 −0.070668 −0.131936 0.190815
1.902509 −0.017952 0.503090 −0.032487 −0.365015
0.010680 −0.023503 −0.002825 0.027884
1.310239 0.135858 −0.504981
0.913140 −0.021506
4.355061

(9)
The third estimate, V¯f , is in (10) and was created through the methodology in Ap-
pendix A.2.
V¯f =

0.013327 0.032698 −0.050611 −0.001625 −0.043772 −0.015142 0.050047
0.749256 0.006666 0.007869 −0.080288 −0.130553 0.205403
1.936482 −0.018418 0.513867 −0.031020 −0.369599
0.010773 −0.023863 −0.002839 0.028431
1.318745 0.139828 −0.515907
0.918900 −0.043385
4.374648

(10)
The three covariance matrix specifications for NPANCOVA produced similar hazard
ratio estimates, standard errors, and p-values. However, the decrease in standard error
using V¯f (as compared to Vf or V˜f ) which was observed in the dichotomous example
for the neurologic disorder data did not occur here.
A.3.3 Dichotomous Outcome: Osteoarthritis Data
Three specifications of the covariance matrix for f were used to produce the analysis
results in Table A.3.3 for the WOMAC outcome for 218 patients previously described in
Chapter 3. The first estimate, Vf , is in (11) and was created through the methodology
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in Chapter 3. The estimated covariance matrices relating to the WOMAC score are as
follows:
Vf =

0.080079 −0.016620 0.002636 −0.414590 −0.468217
1.850647 0.007463 −0.135803 −0.358609
0.003937 −0.029361 −0.033521
8.194083 7.445572
9.009170

(11)
The second estimate, V˜f , is in (12) and was created through the methodology in
Appendix A.1.1.
V˜f =

0.080079 −0.023496 0.002254 −0.410012 −0.460232
2.159682 0.012956 0.054111 −0.297552
0.003895 −0.026881 −0.031389
8.364579 7.208704
8.570754

(12)
The third estimate, V¯f , is in (13) and was created through the methodology in
Appendix A.2.
V¯f =

0.076291 −0.021230 0.002279 −0.394182 −0.459950
1.850647 0.007463 −0.135803 −0.358609
0.003937 −0.029361 −0.033521
8.194083 7.445572
9.009170

(13)
The three covariance matrix specifications produced similar odds ratio estimates,
standard errors, and p-values for the NPANCOVA method. However, the third speci-
fication, V¯f , resulted in an odds ratio slightly further away from the null, and it had a
slightly smaller standard error and p-value than when Vf or V˜f were used.
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Appendix B: Chapter 4
B.1 Specification of Covariance Matrix for Compound Vector
in NPANCOVA for Multiple Treatment Groups
Let j = 1, . . . , ni index patients and i = 1, . . . , s index treatment groups. Meth-
ods for multivariate U-statistics ((Davis and Quade, 1968), (Davis and Quade, 1978),
(Kawaguchi, Koch and Wang, 2011)) are used to obtain the approximate covariance
matrix of βˆ and the difference in means of the covariates (x¯i−x¯s) for the ith treatment
group, the approximate covariance matrix of (x¯i−x¯s), and the approximate covariance
matrix of (x¯i − x¯s) and (x¯i′ − x¯s) where i 6= i′. Let xj be the vector of covariates
for the jth patient. Furthermore, ni is the number of patients randomized to the ith
treatment, and
∑s
i=1 ni = n. Define an indicator rji where rji = 1 if patient j is in
treatment group i and is 0 otherwise. Also define ujii′ = 0.5 if patient j is in treatment
group i, ujii′ = −0.5 if patient j is in treatment group i′, and is 0 otherwise. Then
gii′,jj′ for a pair of patients j and j
′ is defined in (14)
gii′,jj′ =
n(n− 1)rjirj′i′(ujii′ − uj′ii′)(xj − xj′)
2nini′
(14)
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When summing over pairs of patients for comparing groups i and i′, the following is
obtained:
gii′,j∗ =
∑
j′ 6=j
gii′,jj′
n− 1 =
∑
j′ 6=j
nrjirj′i′(ujii′ − uj′ii′)(xj − xj′)
2nini′
=

n(xj−x¯i′ )
2ni
if j from group i
−n(xj−x¯i)
2ni′
if j from group i′
0 if j is not from group i or i′
Summing over all patients j, the following is obtained for the difference in covariate
means between the ith and i′th group:
g¯ii′ =
∑
j
gii′,j∗
n
=
x¯i − x¯i′
2
− x¯i′ − x¯i
2
= x¯i − x¯i′
To obtain the variance of x¯i− x¯i′ , deviations about the mean for the comparison of the
ith and the i′th group are first created:
gii′,j∗ − g¯ii′ =

n(xj−x¯i′ )
2ni
− (x¯i − x¯i′)
=
nxj−nx¯i′−2nix¯i+2nix¯i′
2ni
if j from group i
= n
2ni
(xj − x¯i) + n−2ni2ni (x¯i − x¯i′)
=

−n(xj−x¯i)
2ni′
− (x¯i − x¯i′)
=
−nxj+nx¯i−2ni′ x¯i+2ni′ x¯i′
2ni′
if j from group i′
= −n
2ni′
(xj − x¯i′) + n−2ni′2ni′ (x¯i − x¯i′)
so that
gii′,j∗ − g¯ii′ =

n
2ni
(xj − x¯i) + n−2ni2ni (x¯i − x¯i′) if j from group i
−n
2ni′
(xj − x¯i′) + n−2ni′2ni′ (x¯i − x¯i′) if j from group i
′
−(x¯i − x¯i′) if j not from group i or i′
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With g˜ii′,j =
2√
n(n−1)(gii′,j∗ − g¯ii′), an expression for the variance of g¯ii′ ((Davis and
Quade, 1968),(Davis and Quade, 1978),(Kawaguchi, Koch and Wang, 2011)) is in (15).
V g¯ii′ =
4
n(n− 1)
n∑
j=1
(gii′,j∗ − g¯ii′)(gii′,j∗ − g¯ii′)′
=
n∑
j=1
g˜ii′,jg˜
′
ii′,j
(15)
A vector f j = (r
′
j, g˜
′
1s,j, . . . , g˜
′
(s−1)s,j)
′ can be created which contains the length (s− 1)
vector of DFBETA residuals for the jth patient, rj = (r1s,j, . . . , r(s−1)s,j)′, and the
deviations about the covariate means for the s − 1 comparisons of treatment groups
with the sth treatment group. The mean vector d = (βˆ
′
, (x¯1 − x¯s)′, . . . , (x¯s−1 − x¯s)′)′
contains the estimated log hazard ratios βˆ and differences in means of the P covariates
for the comparisons of the s− 1 treatments with the sth treatment. The variance of d
can then be estimated by the ((P + 1)(s− 1))× ((P + 1)(s− 1)) matrix Vd in (16).
Vd ≈
∑
j
f jf
′
j
=

∑
j rjr
′
j
∑
j r1s,jg˜
′
1s,j . . .
∑
j r(s−1)s,jg˜
′
(s−1)s,j∑
j g˜1s,jg˜
′
1s,j . . .
∑
j g˜1s,jg˜
′
(s−1)s,j
. . .
...∑
j g˜(s−1)s,jg˜
′
(s−1)s,j

(16)
Here, the covariance matrix for βˆ is estimated by
∑
j rjr
′
j, the covariance matrix for
the difference in mean covariates for the ith group and the sth group is approximated
by
∑
j g˜is,jg˜
′
is,j, the covariance of βˆ and the difference in mean covariates for the ith
group and the sth group is approximated by
∑
j ris,jg˜is,j, and the covariance matrix
of the difference in mean covariates for the (i, s) comparison and the (i′, s) comparison
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(i 6= i′) is approximated by ∑j g˜is,jg˜′i′s,j. For large n, these quantities are estimated by
n∑
j=1
g˜is,jg˜
′
is,j =
n(ni − 1)
(n− 1)ni
∑
j∈i
(xj − x¯i)(xj − x¯i)′
ni(ni − 1)
+
n(ns − 1)
(n− 1)ns
∑
j∈s
(xj − x¯s)(xj − x¯s)′
ns(ns − 1)
+
[
(n− 2ni)2
ni(n− 1)n +
(n− 2ns)2
ns(n− 1)n +
4(n− ni − ns)
n(n− 1)
]
(x¯i − x¯s)(x¯i − x¯s)′
≈ Vx¯i + Vx¯s
n∑
j=1
ris,jg˜
′
is,j =
√
n
n− 1(
∑
j∈i
rj(xj − x¯i)′
ni
−
∑
j∈s
rj(xj − x¯s)′
ns
)
+
1√
n(n− 1) [(n− 2ni)r¯i + (n− 2ns)r¯s − 2(n− ni − ns)r¯ /∈i,/∈s] (x¯i − x¯s)
′
=
√
n(ni − 1)
ni(n− 1)
∑
j∈i
rj(xj − x¯i)′√
ni(ni − 1)
−
√
n(ns − 1)
ns(n− 1)
∑
j∈s
rj(xj − x¯s)′√
ns(ns − 1)
+
1√
n(n− 1) [(n− 2ni)r¯i + (n− 2ns)r¯s − 2(n− ni − ns)r¯ /∈i,/∈s] (x¯i − x¯s)
′
≈ Vβˆ,x¯i − Vβˆ,x¯s
n∑
j=1
g˜is,jg˜
′
i′s,j =
1
n2s
∑
j∈s
n
n− 1(xj − x¯s)(xj − x¯s)
′
+
[
(n− 2ns)2
nsn(n− 1) −
2ns(n− 2ni)
nsn(n− 1) −
2ns(n− 2ni′)
nsn(n− 1)
]
(x¯i − x¯s)(x¯i′ − x¯s)′
+
[
4(n− ni − ni′ − ns)
nsn(n− 1)
]
(x¯i − x¯s)(x¯i′ − x¯s)′
=
(ns − 1)n
ns(n− 1)
∑
j∈s
(xj − x¯s)(xj − x¯s)′
ns(ns − 1)
+
[
n
ns(n− 1) −
4
n− 1
]
(x¯i − x¯s)(x¯i′ − x¯s)′
≈ Vx¯s
Note that in the above expressions, the quantity (x¯i−x¯s) has expected value zero on the
basis of a valid randomization which would produce comparable covariate distributions
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between the treatment groups.
B.2 Covariance Matrices for Multivariate Time-to-Event Out-
comes
Extension to multivariate time-to-event outcomes is possible through the creation
of the appropriate covariance matrix for the estimated log hazard ratios and the ma-
trix of covariances of the estimated log hazard ratios with the differences in means of
covariables between the treatment groups.
Marginal Cox proportional hazards models for each of the K events are fit where
treatment is managed as indicators (i.e. with s treatment groups, z1, . . . , zs−1 represent
the s − 1 indicator variables and the sth group is the referent treatment group). Let
R
(t)
i be the ni×K matrix of the DFBETA residuals for K events for the tth treatment
group comparison (t = 1, . . . , s−1) for the ni individuals from the ith treatment group.
Then, via Wei et. al. (Wei, Lin and Weissfeld, 1989), R(t)
′
R(t) =
∑s
i=1R
(t)′
i R
(t)
i is the
robust estimate of the K×K covariance matrix of (βˆ(t)1 , . . . , βˆ(t)K )′ for the tth treatment
comparison. With βˆ = (βˆ
(1)
1 , . . . , βˆ
(1)
K , . . . , βˆ
(s−1)
1 , . . . , βˆ
(s−1)
K )
′ as the stacked K(s−1)×1
vector of estimated log hazard ratios, the following K(s− 1)×K(s− 1) matrix Vβˆ is
in (17).
Vβˆ =

R(1)
′
R(1) R(1)
′
R(2) . . . R(1)
′
R(s−1)
R(2)
′
R(2) . . . R(2)
′
R(s−1)
. . .
...
R(s−1)
′
R(s−1)

(17)
Let X i = (xi1, . . . ,xiP ) be the ni × P matrix of P baseline covariates for the ni
individuals from the ith treatment group. With x¯i = (x¯i1, . . . , x¯iP )
′ representing the
vector of covariate means for group i, the covariance matrix Vx¯i = (X i − 1x¯i′)′(X i −
1x¯i
′)/[ni(ni − 1)] = A′iAi is the estimated covariance matrix of the covariate means
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for group i and 1 is a ni × 1 vector of ones. Here, Ai = (X i − 1x¯i′)/
√
ni(ni − 1).
LetRi = (R
(1)
i , . . . ,R
(s−1)
i ) be the ni×K(s−1) matrix of DFBETA residuals for the
K events within s−1 treatment comparisons for the ni individuals in the ith treatment
group. Then the covariance between βˆ and (x¯i − x¯s) is given as Vβˆ,x¯1 − Vβˆ,x¯s =
R′iAi −R′sAs.
Let d = (βˆ
′
, (x¯1 − x¯s)′, . . . , (x¯s−1 − x¯s)′)′ be the ((K + P )(s − 1)) × 1 vector of
estimated log hazard ratios and differences in baseline covariate means for the s − 1
treatment group comparisons with the sth treatment group. Then Vd is the covariance
matrix of d and has the structure in (18).
Vd =

Vβˆ Vβˆ,x¯1 − Vβˆ,x¯s Vβˆ,x¯2 − Vβˆ,x¯s . . . Vβˆ,x¯s−1 − Vβˆ,x¯s
Vx¯1 + Vx¯s Vx¯s . . . Vx¯s
. . . . . .
...
. . . Vx¯s
Vx¯s−1 + Vx¯s

(18)
Weighted least squares is then used to produce covariate-adjusted estimates b of the
log hazard ratios by forcing the difference in means for the covariables to zero. This has
invocation for d by fitting the model Z = [IK(s−1) 0K(s−1)×P (s−1)]′ to d, where IK(s−1)
is a K(s − 1) ×K(s − 1) identity matrix and 0K(s−1)×P (s−1) is a K(s − 1) × P (s − 1)
matrix of zeroes. The covariate-adjusted estimator b is given in (19).
b = (Z ′Vd−1Z)−1Z ′Vd−1d (19)
and a consistent estimator for the covariance matrix of b is Vb in (20).
Vb = (Z
′Vd−1Z)−1 (20)
111
These estimators b have an approximate multivariate normal distribution when the
sample sizes for each treatment group are sufficiently large for d to have an approximate
multivariate normal distribution, with this usually being sufficient sample size for the
βˆ
(t)
to have approximate multivariate normal distributions through enough events for
each k = 1, . . . , K in a non-redundant manner. As the differences in means of the
covariables between treatment groups are expected to be zero due to randomization,
the extent of random imbalances between groups for the means of the covariates may
be evaluated through Q0 in (21).
Q0 = (d−Zb)′Vd−1(d−Zb) (21)
This criterion approximately has the chi-squared distribution with P (s− 1) degrees of
freedom.
Homogeneity of the adjusted log hazard ratios in b across the K event outcomes
(but within a treatment group comparison) can have assessment with the criterion Qh,b
in (22).
Qh,b = b
′C ′(CVbC ′)−1Cb (22)
where C = Is−1 ⊗ [I(K−1) − 1(K−1)], and ⊗ represents the Kronecker product such
that every element in Is−1 multiplies the matrix [I(K−1) − 1(K−1)]. This criterion
approximately has the chi-squared distribution with (K− 1)(s− 1) degrees of freedom.
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